Vaccine adjuvants and formulations

Vaccine formulations with alpha-lactalbumin and metabolizable oils like zymosan and MONTANIDE™ induce both type 1 and type 17 T cell responses, addressing the limitations of current vaccines and providing a safe, effective immune activation against breast cancer.

JP2024156845AInactive Publication Date: 2024-11-06THE CLEVELAND CLINIC FOUND
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024125875
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-02-15
Filing Date
2024-08-01
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current vaccine formulations fail to induce both type 1 and type 17 immune responses, which are essential for effective breast cancer treatment, particularly in triple-negative breast cancer (TNBC), and existing adjuvants like Complete Freund's Adjuvant are toxic for human use.

Method used

Development of vaccine formulations comprising alpha-lactalbumin polypeptides and metabolizable oils, such as zymosan and MONTANIDE™, which induce both type 1 and type 17 T cell responses without toxicity, using a water-in-oil emulsion to enhance immune activation.

Benefits of technology

The formulations effectively induce a strong immune response against breast cancer, including TNBC, by promoting both type 1 and type 17 T cell activation, reducing granuloma formation, and providing a safe alternative to toxic adjuvants.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156845000001_ABST
    Figure 2024156845000001_ABST
Patent Text Reader

Abstract

To provide compositions that induce immune response including both type 1 and type 17 T-cells with limited induction of toxicity or without inducing toxicity at all.SOLUTION: Provided are compositions containing an antigen, a carbohydrate and a metabolizable oil, methods of administering such compositions to a subject, methods of producing such compounds, and related compositions, methods and uses.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

Detailed Description of the Invention

[0001] [Technical field] Related Applications This application claims priority to U.S. Provisional Patent Application No. 62 / 806,422, filed February 15, 2019, the entire contents of which are incorporated herein by reference for all purposes.

[0002] Sequence Listing This specification references a Sequence Listing (submitted electronically as a .txt file entitled "CCI_005_Seq_Listing.txt" on February 13, 2020). This .txt file was generated on February 13, 2020 and is 6kb in size. The entire contents of the Sequence Listing are incorporated herein by reference.

[0003] [Background technology] Vaccines generally contain at least two major components: an immunogen, which serves as a target for the adaptive immune response, and an adjuvant, which enhances the adaptive immune response. Complete Freund's adjuvant (CFA) is a suspension of killed mycobacterial cells in a liquid prepared from non-metabolizable oil. CFA is widely considered the "gold standard" against which all other adjuvants are compared, due to its proven efficacy for over 70 years in inducing adaptive immunity. However, CFA cannot be used as an adjuvant for human vaccination due to its toxic effects, primarily related to the induction of unresolved granulomas and abscesses at the vaccination site.

[0004] Therefore, there is a need for suitable adjuvants for human vaccination that can also promote the induction of strong immune responses.

[0005] Breast cancer is the second leading cause of cancer-related deaths in women. There are several different genetic subtypes of breast cancer, and treatments are generally targeted to specific subtypes. For example, hormone therapy and drugs that target the estrogen receptor (ER) are designed to treat ER-positive cancers. Triple-negative breast cancer (TNBC) is the most aggressive and most deadly form of breast cancer and is notoriously difficult to treat. TNBC cancer cells are estrogen receptor (ER), progesterone (PR), and HER2 negative, so drugs designed to treat these receptors are ineffective against TNBC.

[0006] There is a need for effective breast cancer therapies for difficult-to-treat breast cancer subtypes, including TNBC.

[0007] Summary of the Invention Most current clinical vaccine formulations induce proinflammatory type 1 T cell responses that produce interferon gamma (IFNγ), but few induce type 17 T cell responses that produce interleukin-17 (IL-17). The present invention encompasses the insight that many current clinical vaccine formulations are ineffective because they do not induce both type 1 and type 17 immune responses. In accordance with the present invention, compositions are provided that induce immune responses that include both type 1 and type 17 T cells while inducing limited or no toxicity.

[0008] The present invention also encompasses the development of vaccine formulations that induce adaptive immune responses that are effective in inhibiting and / or preventing the growth of breast cancer.The currently disclosed compositions comprise alpha-lactalbumin polypeptide antigens and adjuvant components, as further described herein.Alpha-lactalbumin is constitutively overexpressed in the majority of TNBCs, and in a lower proportion in other forms of breast tumors.Therefore, the vaccine formulations, compositions, and methods of the present disclosure may be useful in the treatment and / or prevention of the most aggressive breast cancers.

[0009] In one aspect, a composition is provided comprising a carbohydrate and a metabolisable oil, where (i) the composition further comprises an antigen, or (ii) the carbohydrate comprises a polysaccharide, and the composition comprises a mixture of at least two polysaccharides.

[0010] In some embodiments, the antigen is a tumor-associated antigen.

[0011] In some embodiments, the carbohydrate comprises a polysaccharide and the composition comprises a mixture of at least two polysaccharides.

[0012] In some embodiments, the composition comprises a tumor-associated antigen, the carbohydrate comprises a polysaccharide, and the composition comprises a mixture of at least two polysaccharides.

[0013] In some embodiments, a composition that (i) comprises an antigen, or (ii) further comprises an antigen, when administered to a subject, is capable of inducing an antigen-specific T cell immune response, including both type 1 and type 17 inflammatory T cell responses.

[0014] In some embodiments, the carbohydrate binds to a pattern recognition receptor. For example, the pattern recognition receptor can be TLR2 or Dectin-1.

[0015] In some embodiments, the mixture of polysaccharides comprises at least three polysaccharides.

[0016] In some embodiments, the polysaccharide or each polysaccharide in the mixture is selected from the group consisting of chitin, dextran, glucan, lentanan, mannan, and combinations thereof.

[0017] In some embodiments, the polysaccharide or mixture of polysaccharides comprises a glucan, such as a β-glucan (e.g., 1-3 β-glucan). For example, the mixture of polysaccharides can comprise a mixture of chitin, glucan, and mannan. In some embodiments, at least 50% of the carbohydrates in the composition are β-glucans.

[0018] In some embodiments, the composition comprises zymosan.

[0019] In some embodiments, the metabolizable oil comprises a refined oil. For example, the refined oil can be a mineral oil, such as DRAKEOL™ 6VR.

[0020] In some embodiments, the metabolizable oil comprises a biodegradable oil. For example, the biodegradable oil can be isopropyl myristate, squalene oil, squalane oil, vegetable oil, or a combination thereof. In some embodiments, the biodegradable oil is a vegetable oil, such as a vegetable oil selected from the group consisting of almond oil, castor oil, daikon radish oil, coconut oil, corn oil, cottonseed oil, olive oil, peanut oil, apricot kernel oil, safflower oil, and soybean oil.

[0021] In some embodiments, the metabolizable oil is a pharmaceutical grade oil.

[0022] In some embodiments, the composition further comprises a surfactant, such as mannide monooleate, isomannide monooleate, or a combination thereof. In some embodiments, the surfactant comprises mannide monooleate. For example, the composition can comprise MONTANIDE™, such as MONTANIDE™ ISA51VG.

[0023] In some embodiments, the composition is a water and oil emulsion, for example a water-in-oil emulsion.

[0024] In some embodiments, the antigen comprises a polypeptide antigen. In some embodiments, the polypeptide antigen is a retired autoantigen.

[0025] In some embodiments, the polypeptide antigen comprises an alpha-lactalbumin polypeptide. For example, the alpha-lactalbumin polypeptide may have an amino acid sequence comprising at least 8 consecutive amino acids of SEQ ID NO:5.

[0026] In some embodiments, the antigen and carbohydrate (or mixture of polysaccharides) are present in a ratio of about 10:1 to about 1:10 (w / w). In some embodiments, the antigen and carbohydrate (or mixture of polysaccharides) are present in a ratio of about 1:1 (w / w).

[0027] In some embodiments, the composition further comprises a pharma- ceutically acceptable carrier.

[0028] In some embodiments, the composition further comprises an antibiotic.

[0029] In one aspect, a method is provided that includes administering to a subject a therapeutically effective amount of a composition disclosed herein, e.g., a composition that includes an antigen, a carbohydrate, and a metabolizable oil.

[0030] In some embodiments, the subject is a mammal, for example a human.

[0031] In some embodiments, the subject is a non-lactating female subject.

[0032] In some embodiments, the subject has cancer or is at risk of developing cancer.

[0033] In some embodiments, the subject has not been diagnosed with cancer.

[0034] In some embodiments, the cancer is breast cancer, e.g., metastatic breast cancer, primary breast cancer, and / or triple negative breast cancer.

[0035] In some embodiments, the cancer comprises cells that overexpress alpha-lactalbumin.

[0036] In some embodiments, a therapeutically effective amount includes two or more doses, for example, three or more doses, hi some embodiments, a therapeutically effective amount includes three or fewer doses.

[0037] In some embodiments, each dose is administered one or more weeks apart, for example at least four weeks apart, hi some embodiments, each dose is administered about four weeks apart.

[0038] In some embodiments, each dose contains about the same amount of antigen, hi some embodiments, each dose contains about the same amount of antigen and the same amount of carbohydrate.

[0039] In some embodiments, each dose contains from about 1 μg to about 5 mg, for example, from about 50 μg to about 2 mg, or from about 100 μg to about 1 mg of antigen.

[0040] In some embodiments, the compositions are administered by subcutaneous, intradermal, subdermal, or intramuscular injection.

[0041] In some embodiments, administration of the composition induces an antigen-specific T cell immune response. In some embodiments, the T cell immune response comprises CD4+ T cells, CD8+ T cells, or both. In some embodiments, the T cell immune response comprises a type 1 or type 17 proinflammatory T cell response. In some embodiments, the T cell immune response comprises both a type 1 and type 17 proinflammatory T cell response.

[0042] In some embodiments, administration causes a decrease in granuloma formation compared to a reference level, e.g., the level of granuloma formation observed in a subject administered a composition comprising complete Freund's adjuvant.

[0043] In some embodiments, an additional anti-cancer therapeutic has been, will be, or is simultaneously administered to the subject, e.g., an anti-cancer therapeutic comprising an anti-cancer agent, hi some embodiments, the additional anti-cancer agent is selected from the group consisting of bevacizumab, bleomycin, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, etoposide, gemcitabine, letrozole, olaparib, tamoxifen, topotecan, trabectin, CTLA4 antibody, PD-1 antibody, PD-L1 antibody, and TGFβ antibody.

[0044] In some embodiments, a composition is provided comprising an alpha-lactalbumin polypeptide, zymosan, and MONTANIDE™, wherein the alpha-lactalbumin polypeptide comprises an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, the alpha-lactalbumin polypeptide comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 5.

[0045] In one aspect, there is provided a formulation comprising an alpha-lactalbumin polypeptide, zymosan, and a water-in-oil emulsion of MONTANIDE™, wherein the alpha-lactalbumin polypeptide and zymosan are present in the formulation in a ratio of about 1:5 (w / w) to 5:1 (w / w), and the alpha-lactalbumin polypeptide comprises an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, the alpha-lactalbumin polypeptide comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 5.

[0046] In one aspect, there is provided a method of making a composition or formulation disclosed herein, comprising mixing an aqueous solution comprising an antigen with an emulsion comprising a carbohydrate and a metabolizable oil, in some embodiments, the ratio of aqueous solution to emulsion is about 1:2 to about 2:1 (v / v), e.g., about 1:1 (v / v).

[0047] In one aspect, there is provided a use of a composition or formulation disclosed herein for the manufacture of a medicament for preventing, treating, or ameliorating cancer.

[0048] BRIEF DESCRIPTION OF THE DRAWINGS [Figure 1] Induction of inflammatory T cell immunity by vaccination with α-lactalbumin / complete Freund's adjuvant (CFA) emulsion. The mean splenocyte frequency of inflammatory T cells producing IFNγ (type 1) and IL-17 (type 17) was measured 4 weeks after vaccination of 6-8 week-old BALB / c female mice (n=3) with 200 μl of water-in-oil emulsion containing 100 μg of recombinant mouse α-lactalbumin and 200 μg of Mycobacteria tuberculosis H37RA strain in complete Freund's adjuvant (CFA). Error bars indicate ±SD.

[0049] Figure 2 shows a comparison of several adjuvants with CFA in the induction of type 1 / type 17 T cell immunity. Splenocyte frequencies of type 1 and type 17 inflammatory T cells were measured 4 weeks after immunization of 6-8 week-old BALB / cJ female mice with 200 μL of emulsion containing 100 μg of recombinant mouse α-lactalbumin and conventional doses of various adjuvants, including CFA. Data are expressed as the mean α-lactalbumin-specific type 1 and type 17 spot-forming units (SFU) obtained using each test adjuvant divided by the SFU obtained on the same day using CFA as the "gold standard" adjuvant. The horizontal black dotted line indicates the frequency equivalent to that obtained using CFA as the adjuvant (SFU induced using CFA = 1). Some immunizations were performed twice, 2 weeks apart, and are shown as ×2.

[0050] Figure 3 shows the growth of 4T1 mouse mammary tumors using different α-lactalbumin / adjuvant combinations. Figure 3A shows female BALB / cJ mice were vaccinated subcutaneously at 6-8 weeks of age with 200 μL of an emulsion containing 100 μg of recombinant mouse α-lactalbumin and 200 μg of CFA. Control mice were vaccinated with 200 μg of CFA alone. Two weeks after vaccination, mice were vaccinated with 2 × 10 44T1 mouse breast tumor cells were inoculated subcutaneously and tumor growth was measured every other day using a caliper. This same protocol was then used to measure tumor growth for various other adjuvants shown in Figure 2, including (Figure 3B) GPI-0100 x2, (Figure 3C) Sigma lipid A, (Figure 3D) AS02B lipid A, (Figure 3E) CpG DNA x2, (Figure 3F) CpG DNA+α-Gal-Cer x2, (Figure 3G) β-glucan peptide in IFA, and (Figure 3H) zymosan in IFA, using the manufacturer's recommended doses. Some vaccinations were given twice, 2 weeks apart, and are shown as x2. Asterisks indicate significant differences between test and control vaccinated mice (P<0.05).

[0051] FIG. 4. Induction of type 1 / type 17 inflammatory T cells using Zymosan / IFA, Zymosan / MONTANIDE™. Six to eight week old female BALB / cJ mice were vaccinated with an emulsion containing 100 μg of aqueous phase recombinant mouse α-lactalbumin emulsified with 200 μg of zymosan in either 100 μL IFA or 100 μL MONTANIDE™. Four weeks after vaccination, splenocyte frequencies of inflammatory type 1 (IFNγ) and type 17 (IL-17) T cells were measured by ELISPOT analysis. Data represent the mean spot forming units (SFU) of recall responses to 50 μg / mL recombinant mouse α-lactalbumin minus the mean background response of cultures without recall antigen (mean background <5 SPU per assay). Error bars indicate ±SE.

[0052] Figure 5 shows the results of the vaccine dose test. Eight-week-old female BALB / cJ mice were subcutaneously vaccinated in the flank with 200 μl of emulsion containing equal amounts of α-lactalbumin and zymosan ranging from 100 to 1000 μg each. Recombinant mouse α-lactalbumin (FLAG-N-mαlac-C-HIS) was dissolved in sterile USP grade water, and zymosan was suspended in MONTANIDE™ ISA51VG. Groups of three mice were vaccinated once, twice, or three times, each with a 4-week interval. Four weeks after the final vaccination, splenocytes were subjected to ELISPOT analysis using capture / antibody pairs specific for mouse IFNγ, IL-5, and IL-17 to evaluate the splenocyte frequencies of generated type 1, type 2, and type 17 T cell lineages, respectively.

[0053] FIG. 6 shows the change in body weight from the time of the first vaccination of mice in single-vaccination group A in the toxicology study described in Example 5.

[0054] FIG. 7 shows the change in body weight from the first vaccination of double-vaccinated Group B mice in the toxicology study described in Example 5.

[0055] Figure 8 shows the change in body weight from the time of first vaccination of triple-vaccinated Group C mice in the toxicology study described in Example 5. Body weight changes were normalized to the body weight obtained on day 0 (set at 100%) and plotted as a percentage increase or decrease relative to this initial starting point. Body weights were recorded for each mouse at the same time. Arrows indicate the day(s) of vaccination. Error bars indicate ±SE.

[0056] FIG. 9 shows the change in body temperature from the time of the first vaccination in single-vaccination Group A mice in the toxicology study described in Example 5.

[0057] FIG. 10 shows the change in body temperature from the time of the first vaccination in double-vaccinated Group B mice in the toxicology study described in Example 5.

[0058] FIG. 11 shows the change in body temperature from the time of first vaccination of triple-vaccinated Group C mice in the toxicology study described in Example 5. The change in body temperature was normalized to the temperature obtained on day 0 (set as 100%) and plotted as a percentage increase or decrease relative to this initial starting point. Temperatures were recorded at the same time for each mouse. Arrows indicate the day(s) of vaccination. Error bars indicate ±SE.

[0059] FIG. 12 shows the spleen, liver, and kidney weights recorded at necropsy for single vaccinated Group A mice in the toxicology study described in Example 5.

[0060] FIG. 13 shows the spleen, liver, and kidney weights recorded at necropsy for double vaccinated Group B mice in the toxicology study described in Example 5.

[0061] Figure 14 shows spleen, liver, and kidney weights recorded at necropsy for triple-vaccinated Group C mice in the toxicology study described in Example 5. Weights are expressed as a percentage of total body weight, and the average percentages are plotted for each subgroup of mice (as shown in Table 2 in Example 5). Error bars indicate ±SE.

[0062] Figure 15 shows a representative appearance of immunization sites in mice subcutaneously administered Zymosan / MONTANIDE™ / α-lactalbumin emulsion, as further described in Example 5. Figure 15 shows a photograph of the mouse taken approximately 2 weeks after the second injection and approximately 6 weeks after the first injection. The blue arrow indicates the first injection site and the red arrow indicates the second injection site. As Figure 15 shows, the first injection site has an improved appearance compared to the second injection site, indicating resolution of the granuloma over time.

[0063] Figure 16 shows the mean clinical endpoint scores for granulomas at three consecutive injection sites in BALB / c mice subcutaneously injected with Zymosan / MONTANIDE™ / α-lactalbumin emulsion as further described in Example 5. Oily granulomas at the injection sites were commonly observed and were graded according to the following criteria: 0, normal; 1, minimal; 2, mild; 3, moderate; 4, severe. For each injection site, the mean was calculated for all mice (n=25) in all treatment groups. Error bars represent ±SE.

[0064] FIG. 17 shows a summary of the severity of focal hepatitis in all groups in the toxicology study described in Example 5.

[0065] Figure 18 shows the study scheme for the clinical trial described in Example 8. The scheme shows the timeline of dose administration, toxicity assessment, and blood sampling for immunological monitoring.

[0066] [Mode for carrying out the invention] T cells that mediate adaptive immune responses are divided into subsets according to their cytokine profiles. Type 1 proinflammatory T cells produce IFNγ and mediate immunity against viral and bacterial infections, while type 2 regulatory T cells produce interleukin (IL)-4, IL-5, and IL-13 and mediate humoral immunity against parasitic infections. Recent studies have established type 17 inflammatory T cells, which produce IL-17, as a distinct subtype that also plays a prominent role in inflammation. Both type 1 and type 17 T cell lineages are required to induce tissue damage optimized against self-proteins (Steinman et al., (2007) Nat Med 13:139-145; Luger et al., (2008) J Exp Med 205:799-810).

[0067] Anti-cancer vaccines are designed to stimulate the immune system to attack cancer cells. These vaccines usually contain antigens that are preferentially expressed on cancer cells ("tumor-associated antigens"). Most current clinical vaccine formulations induce proinflammatory type 1 immunity, but little type 17 immunity. The present invention encompasses the insight that many current clinical vaccine formulations are ineffective because they do not induce both type 1 and type 17 immune responses. In accordance with the present invention, the compositions provided induce immune responses that include both type 1 and type 17 T cells. Furthermore, the compositions of the present disclosure induce limited or no toxicity when injected into animal models, suggesting their suitability for human clinical use.

[0068] The present invention also includes the insight that vaccine formulations comprising alpha-lactalbumin polypeptide and adjuvant components as disclosed herein can prevent and / or ameliorate breast cancer.Alpha-lactalbumin is constitutively overexpressed in the majority of human TNBC, which is the most aggressive and most lethal form of breast cancer.Therefore, the vaccine formulations, compositions and methods disclosed herein can be useful for treating and preventing the most lethal form of breast cancer.

[0069] overview Provided herein are methods and compositions for the treatment and / or prevention of breast cancer by inducing an immune response against alpha-lactalbumin. As described herein, the disclosure includes immunogen / adjuvant combinations that induce adaptive immune responses (e.g., type 1 and type 17 T cells) to inhibit breast cancer growth. In some embodiments, the composition comprises an alpha-lactalbumin polypeptide and zymosan. In some embodiments, the composition comprises an alpha-lactalbumin polypeptide and MONTANIDE™. In some embodiments, the composition comprises an alpha-lactalbumin polypeptide, zymosan, and MONTANIDE™. The combination of alpha-lactalbumin of the disclosure with zymosan and / or MONTANIDE™ induces high frequencies of type 1 / type 17 T cells associated with effective tumor immunity without the unresolved granuloma induction associated with vaccination with the "gold standard" adjuvant, CFA. Thus, vaccination with a combination of alpha-lactalbumin, zymosan and / or MONTANIDE™ provides a unique method of providing safe and effective immunity against the development of human breast cancer.

[0070] I. Definition For convenience, certain terms employed in the specification, examples, and claims are collected in this section.

[0071] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0072] As used herein, "adjuvant" means a substance that, when administered before, together with, or after administration of an antigen, accelerates, prolongs, and / or enhances the quality and / or strength of the immune response to an antigen compared to the response elicited by administration of the antigen alone.

[0073] As used herein, "anti-cancer therapy" refers to a therapy aimed at treating, ameliorating, and / or reducing the risk or progression of cancer or a cancerous condition. In some embodiments, anti-cancer therapy includes anti-cancer agents, which are drugs used to treat, ameliorate, and / or reduce the risk or progression of cancer or a cancerous condition.

[0074] As used herein, the term "antigen" has its ordinary meaning in the art and refers to any molecule or portion of a molecule that, by itself or in combination with an adjuvant and / or a pharma- ceutically acceptable carrier, generates an immune response, e.g., an antibody and / or T cell response.

[0075] As used herein, the term "administering" means providing a pharmaceutical agent or composition to a subject, and includes, but is not limited to, administration by a medical professional and self-administration.

[0076] As used herein, "biodegradable" when used with respect to a substance means a substance that upon introduction into a cell is broken down by cellular mechanisms (e.g., enzymatic degradation) or hydrolysis into components that the cell can reuse or discard without significant toxic effects to the cell. In some embodiments, the components produced by degradation of the biodegradable substance do not induce inflammation and / or other deleterious effects in vivo. In some embodiments, the biodegradable substance is degraded enzymatically. Alternatively, or in addition, in some embodiments, the biodegradable substance is degraded by hydrolysis.

[0077] The term "immune response" as used herein refers to any response by the immune system to an antigen or antigenic determinant. Exemplary immune responses include humoral immune responses (e.g., production of antigen-specific antibodies (neutralizing or otherwise)) and cellular immune responses (e.g., lymphocyte proliferation). Type 1 inflammatory immune responses are characterized by the production of IFNγ. Type 2 regulatory immune responses are characterized by the expression of IL-4 or IL-5. Type 17 inflammatory immune responses are characterized by the expression of IL-17. In some cases, mixed immune responses can be generated. For example, in some cases, a mixed type 1 / type 17 inflammatory immune response is generated, characterized by the expression of both IFNγ and IL-17.

[0078] As used herein, the phrase "metabolizable oil" refers to an oil that, upon introduction into an organism, (1) can be degraded by the organism or can be excreted from the organism to a greater extent; (2) can be degraded by the organism or can be excreted from the organism more quickly; and / or (3) reduces granuloma formation compared to a reference level, such as the level of granuloma formation in a subject administered complete Freund's adjuvant or the level in a subject administered incomplete Freund's adjuvant. Thus, a "metabolizable oil", as the phrase is used herein, does not need to be fully metabolizable. "Reduced granuloma formation" can be characterized, for example, by one or more of the following: fewer granulomas formed, granulomas that are less severe, granulomas that are less severe more quickly, and granulomas that resolve (partially or completely).

[0079] As used herein, the terms "polypeptide" and "protein" are used interchangeably and generally have their art-recognized meaning of a polymer of at least three amino acids. The term "polypeptide" can refer to polypeptides in their neutral (uncharged) form or salts, and to unmodified or modified polypeptides, for example, by glycosylation, side chain oxidation, or phosphorylation. The term "polypeptide" can also be used to refer to a particular functional class of polypeptide. When used to refer to a functional class of polypeptide, the term is intended to include functional fragments, variants (e.g., allelic variants), and derivatives of the reference polypeptide, as well as full-length wild-type versions of the reference polypeptide. In some embodiments, polypeptides of a particular functional class share at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 97.5% sequence identity at the amino acid level with the full-length version of the reference polypeptide. For example, "alpha-lactalbumin polypeptide" as used herein includes alpha-lactalbumin and polypeptides having an amino acid sequence that has sufficient sequence identity to the amino acid sequence of alpha-lactalbumin (or a portion thereof) to induce an alpha-lactalbumin-specific immune response.

[0080] As used herein, the "percentage of identity" between amino acid sequences is synonymous with the "percentage of homology," which can be determined using the algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 87, 2264-2268, 1990), improved by Karlin and Altschul (Proc. Natl. Acad. Sci. USA 90, 5873-5877, 1993). The described algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al. (J. Mol. Biol. 215, 403-410, 1990). BLAST nucleotide searches are performed using the NBLAST program, score=100, wordlength=12, to obtain nucleotide sequences homologous to the polynucleotides described herein. BLAST protein searches are performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to a reference polypeptide. To obtain gapped alignments for comparison purposes, the method of Altschul et al. Gapped BLAST is utilized as described in (Nucleic Acids Res. 25, 3389-3402, 1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (eg, XBLAST and NBLAST) are used.

[0081] As used herein, the phrase "pharmacologically acceptable carrier" refers to a pharma- ceutically acceptable substance, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, thickener, solvent, or encapsulating material, involved in the transport or transfer of a compound of interest from one organ or part of the body to another. The term "carrier" encompasses both non-covalently bonded and covalently bonded carriers to the compound or composition they transport.

[0082] As used herein, the term "purified" refers to the enrichment of a molecule, compound, or composition relative to other components that normally accompany the molecule, compound, or composition in its natural environment. The term "purified" does not necessarily indicate that complete purity of the molecule, compound, or composition has been achieved. In some embodiments, a "purified" molecule, compound, or composition is at least 90%, at least 95%, or at least 97.5% free from other components.

[0083] As used herein, the term "tumor-associated antigen" has its art-recognized meaning and refers to an antigen whose expression is highly correlated with tumor cells. A tumor-associated antigen may or may not also be expressed in normal cells. In some embodiments, a tumor-associated antigen is overexpressed in tumor cells. In some embodiments, expression of a tumor-associated antigen is correlated with a particular subtype or subtypes of tumor cells.

[0084] As used herein, the terms "subject" and "patient" are used interchangeably and refer to an organism that receives a treatment or vaccine (e.g., by administering a composition or formulation disclosed herein). Examples of subjects and patients include mammals, such as humans or non-human animals.

[0085] As used herein, the phrases "therapeutically effective amount" and "effective amount" mean an amount of an agent effective to produce a desired therapeutic effect in at least a subpopulation of cells in a subject, at a reasonable benefit / risk ratio applicable to any pharmaceutical treatment.

[0086] "Treating" a disease in a subject or a subject having a disease means subjecting the subject to pharmaceutical treatment, e.g., administering a drug, thereby alleviating at least one symptom of the disease or preventing its worsening.

[0087] The term "reference" refers to a sample, standard, or level used for comparison purposes. The phrases "reference standard" and "reference level" may be used interchangeably and refer to a value or number derived from a reference sample or subject. In some embodiments, the sample or subject from which the reference level is derived is matched to the subject sample in at least one of the following criteria: age, weight, disease stage, and overall health.

[0088] For example, in some embodiments, the reference level is a clinical grade or score, or an average clinical grade or score.

[0089] The term "retired self-protein" refers to a self-protein that is no longer expressed at autoimmunogenic levels in normal aging tissue. The term "retired self-antigen" refers to an antigen derived from a retired self-protein. In some embodiments, the retired self-antigen comprises a fragment of a retired self-protein. In some embodiments, the retired self-antigen comprises a full-length version of a retired self-protein.

[0090] As used herein, the term "surfactant" has its art-recognized meaning and refers to a substance that tends to reduce the surface tension between two liquids, between a gas and a liquid, or between a liquid and a solid. In some embodiments, a surfactant is an emulsifier, which is a substance that stabilizes an emulsion.

[0091] II. Composition In one aspect, a composition is provided comprising a carbohydrate and a metabolisable oil, where (i) the composition further comprises an antigen, or (ii) the carbohydrate comprises a polysaccharide, and the composition comprises a mixture of at least two polysaccharides.

[0092] In some embodiments, the antigen is a tumor-associated antigen.

[0093] In some embodiments, the carbohydrate comprises a polysaccharide and the composition comprises a mixture of at least two polysaccharides.

[0094] In some embodiments, the composition comprises a tumor-associated antigen, the carbohydrate comprises a polysaccharide, and the composition comprises a mixture of at least two polysaccharides.

[0095] In some embodiments, when the composition is administered to a subject, the composition induces an antigen-specific T cell immune response comprising at least one of: (i) a type 1 inflammatory response; and (ii) a type 17 inflammatory T cell response.

[0096] In some embodiments, the composition comprising or further comprising an antigen, when administered to a subject, induces an antigen-specific T cell immune response, including both type 1 and type 17 inflammatory T cell responses.

[0097] As further described herein, the composition may further comprise a surfactant.

[0098] A. Carbohydrates In some embodiments, the carbohydrate comprises a polysaccharide, for example, a polysaccharide selected from the group consisting of chitin, dextran, glucan, lentanan, mannan, and combinations thereof.

[0099] In some embodiments, the composition comprises a mixture of polysaccharides, for example a mixture comprising at least three polysaccharides.

[0100] In some embodiments, the polysaccharide or each polysaccharide in the mixture is selected from the group consisting of chitin, dextran, glucan, lentanan, mannan, and combinations thereof.

[0101] In some embodiments, the polysaccharide or mixture of polysaccharides comprises a glucan, such as, but not limited to, a β-glucan, such as 1-3 β-glucan.12 In some embodiments, at least 50% of the carbohydrates in the composition are β-glucans.

[0102] In some embodiments, the mixture of polysaccharides comprises a mixture of chitin, glucan, and mannan.

[0103] In some embodiments, the carbohydrate binds to a pattern recognition receptor, such as TLR2 and / or Dectin-1.

[0104] For example, in some embodiments, the composition includes zymosan. Zymosan is a crude cell wall component mixture of baker's yeast extract from Saccharomyces cerevisiae, consisting primarily of β-glucan (50-57%), mannan, and chitin. The U.S. Food and Drug Administration (FDA) has given these β-glucans derived from yeast extract a GRAS ("Generally Recognized as Safe") rating. Yeast zymosan serves as a rich source of β(1,3) glucan. Yeast-derived β(1,3) glucan appears to stimulate the immune system, in part by activating the innate immune system, as part of the body's basic defense against fungal infections (Huang et al., (2013) Clin Vaccine Immunol 20:1585-1591). Yeast β(1,3) glucan is a polysaccharide composed primarily of β(1-3) linked glucose molecules with periodic β(1-3) branches linked through β(1-6) bonds, more formally known as poly-(1-6)-β-glucopyranosyl-(1-3)-β-D-glucopyranose.

[0105] B. Metabolizable oils As used herein, the phrase "metabolizable oil" refers to an oil that, upon introduction into an organism, (1) can be degraded by the organism or excreted to a greater extent from the organism; (2) can be degraded by the organism or excreted more quickly from the organism; and / or (3) reduces granuloma formation compared to incomplete Freund's adjuvant. Thus, a "metabolizable oil," as the phrase is used herein, does not need to be fully metabolizable. "Reduced granuloma formation" can be characterized, for example, by one or more of fewer granulomas formed, granulomas that are less severe, and granulomas that resolve more quickly.

[0106] In some embodiments, the metabolizable oil comprises mineral oil.

[0107] In some embodiments, the metabolizable oil comprises a refined oil, for example, a refined mineral oil (such as, but not limited to, DRAKEOL™ 6VR).

[0108] In some embodiments, the metabolizable oil comprises biodegradable oil.Non-limiting examples of biodegradable oil include isopropyl myristate, squalene oil (e.g., MF59), squalane oil, vegetable oil, or combinations thereof.In some embodiments, the biodegradable oil is vegetable oil, such as, for example, almond oil, castor oil, daikon radish oil, coconut oil, corn oil, cottonseed oil, olive oil, peanut oil, apricot kernel oil, safflower oil, soybean oil, or combinations thereof.

[0109] In some embodiments, the metabolizable oil comprises fish oil.

[0110] In certain embodiments, the metabolizable oil is a pharmaceutical grade oil.

[0111] C. Surfactants / emulsions In some embodiments, the composition provided comprises one or more surfactants.Non-limiting examples of suitable surfactants include mannide monooleate, isomannide monooleate, and combinations thereof.In some embodiments, the composition comprises mannide monooleate.

[0112] In some embodiments, provided compositions include a MONTANIDE™, e.g., the MONTANIDE™ ISA series of adjuvants, that include a metabolizable oil.

[0113] MONTANIDE™ ISA (ISA = Incomplete Seppic Adjuvant) adjuvants (Seppic SA, Paris, France) are a group of oil / surfactant-based adjuvants in which different surfactants are mixed with non-metabolizable mineral oil, metabolizable oil, or a mixture of the two. They are usually prepared for use as emulsions with aqueous antigen solutions. The various MONTANIDE™ ISA groups of adjuvants are used as water-in-oil emulsions, oil-in-water emulsions, or water-in-oil-in-water emulsions.

[0114] In some embodiments, the composition comprises MONTANIDE™ ISA51, MONTANIDE™ ISA51VG, or any bioequivalent adjuvant derived therefrom (e.g., by replacing oleic acid isolated from olives with oleic acid isolated from another source or synthetic oleic acid). MONTANIDE™ ISA51 is a mixture of highly refined mineral oil (DRAKEOL™ 6VR) and a surfactant (mannide monooleate). MONTANIDE™ ISA51VG is a similar composition in which the oleic acid is obtained from olives rather than from animals.

[0115] In some embodiments, the provided compositions are emulsions of water and oil, e.g., water-in-oil emulsions. Methods for making water-in-oil (w / o) emulsions are well known in the art. Water-in-oil emulsions can be obtained by any of a variety of protocols, e.g., protocols using any of a variety of devices, such as high shear mixers, vortex mixers, and syringes with or without connectors (e.g., T-type or I-type connectors). In some embodiments, the provided compositions include adjuvants that create a depot effect, i.e., adjuvants that slowly release antigens in the same composition in the body, thus prolonging the exposure of immune cells to the antigens (e.g., MONTANIDE™ adjuvants).

[0116] D. Antigen Generally, any molecule or portion of a molecule against which an immune response is desired may be used as an antigen, which may include, but is not limited to, any one of a peptide, a polypeptide, a protein, a cell (or a component thereof), a live attenuated pathogen (or a component thereof), and a heat-killed pathogen (or a component thereof).

[0117] In some embodiments, the antigens are non-self antigens, i.e., they are foreign to the organism to which the composition comprising the antigen is intended to be administered.

[0118] In some embodiments, the antigens are self-antigens in that they are or were expressed in at least some cells of the organism to which the composition comprising the antigen is intended to be administered, hi some embodiments, the antigens are retired self-proteins in that they were once expressed in the organism but are no longer expressed at autoimmunogenic levels in non-malignant mature cells.

[0119] In some embodiments, the antigen is a tumor-associated antigen.

[0120] In some embodiments, provided compositions or formulations comprise a mixture of different antigens.

[0121] The antigen may include one or more modifications, for example, one or more modifications that affect the processing, cellular uptake, immunogenicity and / or stability of the antigen or fragment thereof (e.g., within the peptide / MHC antigen complex).

[0122] In some embodiments, the antigen comprises a polypeptide antigen. The polypeptide antigen may be of any of a variety of lengths, and their sequence may or may not correspond to the sequence of a natural protein. For example, in some embodiments, full-length or nearly full-length proteins may be used as polypeptide antigens. In some embodiments, the antigen or antigen mixture comprises one or more fragments or variants of a protein.

[0123] Alpha-lactalbumin polypeptide In some embodiments, the antigen comprises alpha-lactalbumin polypeptide or its immunogenic fragment.In some embodiments, the antigen comprises multiple (e.g., at least 2, 3, 4, 5, 6, 7, 8, 9, or 10) different alpha-lactalbumin polypeptides or fragments.In some embodiments, the composition provided comprises the nucleic acid encoding alpha-lactalbumin polypeptide instead of or in addition to alpha-lactalbumin polypeptide.

[0124] The LALBA gene encodes α-lactalbumin, a major protein in milk. α-lactalbumin forms the regulatory subunit of the lactose synthase (LS) heterodimer, and β1,4-galactosyltransferase (β4Gal-T1) forms the catalytic component. Together, these proteins enable LS to generate lactose by transferring a galactose moiety to glucose. As a monomer, α-lactalbumin binds avidly to calcium and zinc ions and may have bactericidal or antitumor activity. The human LALBA gene contains five exons.

[0125] Human α-lactalbumin precursor protein has 142 amino acids and a molecular weight of 14,178 Da, and human α-lactalbumin has 123 amino acids. In some embodiments, the α-lactalbumin polypeptide has 123 amino acids. The term "α-lactalbumin polypeptide" is intended to include fragments, variants (e.g., allelic variants), and derivatives thereof. Representative human α-lactalbumin cDNA and human α-lactalbumin protein sequences are known in the art and publicly available from the National Center for Biotechnology Information (NCBI). For example, at least one human UBE2D3 isoform is known. The human UBE2D3 isoform (NP_002280.1) can be encoded by a transcript variant (NM_002289.2). The nucleic acid and polypeptide sequences of alpha-lactalbumin orthologues in organisms other than humans are known and include, for example, chimpanzee alpha-lactalbumin (XM_016924811.2 and XP_016780300.1), monkey alpha-lactalbumin (XM_001102116.2 and XP_001102116.1), dog alpha-lactalbumin (NM_001003129.1 and NP_001003129.1), bovine alpha-lactalbumin (NM_174378.2 and NP_776803.1), mouse alpha-lactalbumin (NM_010679.1 and NP_034809.1), and rat alpha-lactalbumin (NM_012594.1 and NP_036726.1). Each of the above mRNA and protein sequences are incorporated herein by reference. Representative sequences of alpha-lactalbumin orthologues are shown in Table 1 below.

[0126] [Table 1]

[0127] *Table 1 includes RNA nucleic acid molecules (e.g., in which thymines are replaced with uridines), nucleic acid molecules encoding orthologs of LALBA, as well as DNA or RNA nucleic acid sequences having a nucleic acid sequence that has at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more identity over their entire length to the nucleic acid sequence of any SEQ ID NO: set forth in Table 1, or a portion thereof. Such nucleic acid molecules can have the function of the full-length nucleic acid, as further described herein.

[0128] *Table 1 includes orthologs of LALBA, as well as polypeptide molecules having amino acid sequences that have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or more identity over their entire length to the amino acid sequence of any SEQ ID NO: set forth in Table 1, or a portion thereof. Such polypeptides may have the function of the full-length polypeptides, as further described herein.

[0129] In some embodiments, the present invention provides an alpha-lactalbumin polypeptide and / or a nucleic acid encoding an alpha-lactalbumin polypeptide.An alpha-lactalbumin polypeptide is a polypeptide that has an amino acid sequence that has sufficient sequence identity with the amino acid sequence of alpha-lactalbumin or a portion thereof and induces an alpha-lactalbumin specific immune response.

[0130] In some embodiments there is provided a fusion polypeptide comprising an alpha-lactalbumin polypeptide and a heterologous polypeptide.

[0131] In certain embodiments, the alpha-lactalbumin polypeptide has an amino acid sequence that includes at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, or 140 consecutive amino acids of the alpha-lactalbumin amino acid sequence set forth in Table 1 (e.g., SEQ ID NO: 1, 3, or 5). In some embodiments, the consecutive amino acids are identical to the alpha-lactalbumin amino acid sequence set forth in Table 1.

[0132] In certain embodiments, the alpha-lactalbumin polypeptide has an amino acid sequence consisting essentially of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, or 140 consecutive amino acids of the alpha-lactalbumin amino acid sequence set forth in Table 1. In some embodiments, the consecutive amino acids are identical to the amino acid sequence of the alpha-lactalbumin amino acid sequence set forth in Table 1.

[0133] In certain embodiments, the alpha-lactalbumin polypeptide has an amino acid sequence consisting of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, or 140 consecutive amino acids of the alpha-lactalbumin amino acid sequence. In some embodiments, the consecutive amino acids are identical to the alpha-lactalbumin amino acid sequence set forth in Table 1.

[0134] In some embodiments, the alpha-lactalbumin polypeptide has an amino acid sequence comprising 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, or 140 consecutive amino acids that are at least 70%, 75%, 80%, 85%, 90%, ... In some embodiments the contiguous amino acids are identical to an alpha-lactalbumin amino acid sequence set forth in Table 1.

[0135] In some embodiments the alpha-lactalbumin polypeptide has an amino acid sequence comprising at least 8 consecutive amino acids of SEQ ID NO:5.

[0136] In some embodiments, the alpha-lactalbumin polypeptide has an amino acid sequence consisting essentially of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, or 140 contiguous amino acids that are at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the alpha-lactalbumin amino acid sequence set forth in Table 1. In some embodiments the contiguous amino acids are identical to an alpha-lactalbumin amino acid sequence set forth in Table 1.

[0137] In some embodiments, the alpha-lactalbumin polypeptide has an amino acid sequence of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, or 140 consecutive amino acids that are at least 70%, 75%, 80%, 85%, 90%, ... In some embodiments the contiguous amino acids are identical to an alpha-lactalbumin amino acid sequence set forth in Table 1.

[0138] As known to those skilled in the art, polypeptides with substantial sequence similarity can induce the same or very similar immune response in host organisms.Thus, in some embodiments, alpha-lactalbumin polypeptides that are derivatives, equivalents, variants, fragments or mutants of alpha-lactalbumin can also be suitable for use in the methods and compositions provided herein.

[0139] In some embodiments, the alpha-lactalbumin polypeptides provided are functional equivalents in that they have amino acid sequences that are modified (for example, by conservative substitution) relative to the sequence of alpha-lactalbumin polypeptide, but still induce immune response.As used herein, the term "conservative substitution" refers to the substitution of amino acid residue with another biologically similar residue.It is well known in the art that the amino acids in the same conservative group can be substituted for each other without substantially affecting the function or immunogenicity of protein.

[0140] In some embodiments, the present invention provides a nucleic acid, such as a DNA molecule, encoding the alpha-lactalbumin polypeptide described herein. In some embodiments, the present invention provides a composition comprising an expression vector comprising an open reading frame encoding an alpha-lactalbumin polypeptide. In some embodiments, the alpha-lactalbumin nucleic acid comprises a regulatory element that promotes the expression of the open reading frame. Such elements may, for example, comprise one or more of a promoter, an initiation codon, a stop codon, and a polyadenylation signal. In addition, they may comprise one or more enhancers. These elements may be operably linked to the sequence encoding the alpha-lactalbumin polypeptide.

[0141] Examples of promoters include, but are not limited to, promoters from Simian Virus 40 (SV40), Mouse Mammary Tumor Virus (MMTV) promoter, Human Immunodeficiency Virus (HIV) such as the HIV long terminal repeat (LTR) promoter, Moloney Virus, Cytomegalovirus (CMV) such as the CMV immediate early promoter, Epstein-Barr Virus (EBV), Rous Sarcoma Virus (RSV), and promoters from human genes such as human actin, human myosin, human hemoglobin, human muscle creatine, human metallothionein, etc. Examples of suitable polyadenylation signals include, but are not limited to, the SV40 polyadenylation signal and the LTR polyadenylation signal.

[0142] Non-limiting examples of enhancers or enhancer / promoters include enhancers from human actin, human myosin, human hemoglobin, human muscle creatine, as well as viral enhancers, such as enhancers from CMV, RSV, and EBV.

[0143] In some embodiments, the nucleic acid provided is incorporated into a carrier or delivery vector. Useful delivery vectors include, but are not limited to, biodegradable microcapsules, immune stimulating complexes (ISCOMs), liposomes, and genetically modified, attenuated live carriers such as viruses or bacteria.

[0144] In some embodiments, the vector is a viral vector, non-limiting examples of which include lentivirus, retrovirus, herpes virus, adenovirus, adeno-associated virus, vaccinia virus, baculovirus, fowlpox virus, avian pox virus, modified vaccinia Ankara (MVA) virus, and other recombinant viruses. For example, vaccinia viral vectors can be used to infect dendritic cells.

[0145] F. Pharmaceutical Compositions and Formulations In some embodiments, the antigen and carbohydrate are present in a ratio of about 10:1 to about 1:10 (w / w), e.g., about 5:1 to about 1:5 (w / w), about 4:1 to 1:4 (w / w), about 3:1 to about 1:3 (w / w), or about 1:2 to about 2:1 (w / w). In some embodiments, the antigen and carbohydrate are present in a ratio of about 1:1 (w / w).

[0146] In some embodiments, provided compositions comprise an antigen, zymosan, and MONTANIDE™. In some such embodiments, the antigen is a polypeptide antigen.

[0147] For example, a composition that may be suitable for the treatment and / or prevention of breast cancer may comprise an alpha-lactalbumin polypeptide, zymosan, and MONTANIDE™, where the alpha-lactalbumin polypeptide comprises an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to the amino acid sequence of SEQ ID NO: 5. In some embodiments, the alpha-lactalbumin polypeptide comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 5.

[0148] In some embodiments, provided compositions are formulated as an emulsion of water and oil, for example a water-in-oil emulsion.

[0149] In some embodiments, a formulation is provided that comprises a water-in-oil emulsion of an antigen, zymosan, and MONTANIDE™, hi some such embodiments, the antigen is a polypeptide antigen.

[0150] For example, in some embodiments, the formulation comprises a water-in-oil emulsion of alpha-lactalbumin polypeptide, zymosan, and MONTANIDE™, where the alpha-lactalbumin polypeptide and zymosan are present in the formulation in a ratio of about 1:5 (w / w) to 5:1 (w / w), and the alpha-lactalbumin polypeptide comprises an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to the amino acid sequence of SEQ ID NO: 5. In some such embodiments, the alpha-lactalbumin polypeptide comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 5.

[0151] In some aspects, pharmaceutical compositions (e.g., vaccine compositions) are provided herein. For example, in some embodiments, the compositions provided further comprise a pharma- ceutically acceptable carrier.

[0152] In some embodiments, the composition further comprises an antibiotic. The pharmaceutical compositions disclosed herein may be specially formulated for administration in solid or liquid form, including those compatible with: (1) oral administration, such as drenches (aqueous or non-aqueous solutions or suspensions), tablets (e.g., for buccal, sublingual targeted, or systemic absorption), boluses, powders, granules, or pastes (e.g., for application to the tongue); or (2) parenteral administration, such as by subcutaneous, intramuscular, intravenous, or epidural injection. Non-limiting examples of formulations suitable for parenteral administration include sterile solutions, sterile suspensions, and sustained release formulations.

[0153] Methods of preparing these formulations or compositions may include the step of bringing into association the antigen with a carbohydrate, a metabolizable oil, a pharma- ceutically acceptable carrier, and, optionally, one or more accessory ingredients. Generally, the formulations may be prepared by uniformly and intimately bringing into association one or more of the composition components described herein with a liquid pharma- ceutically acceptable carrier, a finely divided solid pharma- ceutically acceptable carrier, or both, and then, if necessary, shaping the product. Pharmaceutical compositions suitable for parenteral administration may be provided as pharma- ceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions. Alternatively, or in addition, pharmaceutical compositions for parenteral administration may be provided as sterile powders, which may be reconstituted immediately before use into sterile injection solutions or dispersions. Such injection solutions may contain one or more agents that render the formulation isotonic with the blood of the intended recipient, one or more suspending agents and / or one or more thickening agents. For example, injection solutions may contain one or more of sugars, alcohols, antioxidants, buffers, bacteriostatic agents, and solutes.

[0154] Examples of suitable aqueous and non-aqueous pharma- ceutically acceptable carriers include, but are not limited to, water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof; vegetable oils such as olive oil; and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials (such as lecithin), by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. The pharmaceutical compositions disclosed herein may be formulated as emulsions. For example, vaccine compositions formulated as emulsions are provided, which provide an alternative to aluminum-based vaccines. Emulsion formulations may be prepared by emulsifying antigens dissolved in aqueous buffer with oils, such as any metabolizable oil, as further described herein. Emulsion formulations may form short-lived depots to facilitate phagocytosis of the vaccine by innate immune cells, resulting in an immune response (Leenaars, Koedam et al. 1998). The oils used in such emulsions may provide unique immune stimulation and result in a stronger immune response than vaccines containing alum adjuvants (De Gregorio, Caproni et al. 2013).

[0155] In some embodiments, the disclosure provides a pharmaceutical composition comprising an emulsion, e.g., a water-in-oil emulsion, comprising an antigen and a metabolizable oil, as described herein. For example, in some embodiments, the disclosure provides a pharmaceutical composition comprising an alpha-lactalbumin polypeptide, zymosan, and a metabolizable oil.

[0156] In certain embodiments, the disclosure provides pharmaceutical compositions comprising about 40-60% v / v aqueous phase antigen emulsified with about 40-60% v / v metabolizable oil (optionally incorporating carbohydrate as further described herein). For example, the pharmaceutical composition may comprise about 0.1-25 mg / mL (e.g., 0.5-5 mg / mL) antigen in about a 50% v / v metabolizable oil / carbohydrate composition.

[0157] In some embodiments, the emulsion of the pharmaceutical composition disclosed herein is formed by mixing the aqueous phase antigen with the metabolizable oil in a ratio of about 1.5:1 to about 1:1.5, such as about 1.5:1, about 1.4:1, about 1.3:1, about 1.2:1, about 1.1:1, about 1:1, about 1:1.1, about 1:1.2, about 1:1.3, about 1:1.4, or about 1:1.5, or any value therebetween. In some embodiments, the carbohydrate is suspended in the metabolizable oil before forming the emulsion. In some embodiments, the zymosan is suspended in the metabolizable oil before forming the emulsion.

[0158] The pharmaceutical compositions disclosed herein may be formulated into pharma- ceutically acceptable dosage forms by conventional methods known to those of skill in the art.

[0159] The metabolizable oils and / or carbohydrates in provided pharmaceutical compositions can, in some embodiments, act as adjuvants to increase the immunogenicity of the pharmaceutical composition.

[0160] In some embodiments, an additional physiologically acceptable adjuvant is used. Such additional adjuvant may be used or included in any of several ways, including, but not limited to, (i) mixed with other components in the pharmaceutical composition provided herein after reconstitution of the antigen (e.g., polypeptide antigen) and optionally emulsified with a metabolizable oil as defined above, (ii) part of the reconstituted antigen-containing composition provided herein, (iii) physically linked to the antigen(s) to be reconstituted; and (iv) administered separately to a subject. The additional adjuvant may, for example, provide sustained release of the antigen (e.g., the additional adjuvant may be a liposome), and / or the additional adjuvant may be an adjuvant that is itself immunogenic and thereby functions synergistically with the antigen (i.e., the antigen present in the composition provided).

[0161] For example, the additional adjuvant may be a known adjuvant or other substance that enhances antigen uptake, recruits immune system cells to the site of administration, and / or enhances immune activation of responding lymphocytes. Examples of suitable additional adjuvants include, but are not limited to, immunomodulatory molecules (e.g., cytokines), oil and water emulsions, aluminum hydroxide, glucan, dextran sulfate, iron oxide, sodium alginate, bactoadjuvant, synthetic polymers such as polyamino acids, and copolymers of amino acids, saponin, paraffin oil, and muramyl dipeptide. In some embodiments, the additional adjuvant is Adjuvant 65, α-GalCer, aluminum phosphate, aluminum hydroxide, calcium phosphate, β-glucan peptides, CpG DNA, GM-CSF, GPI-0100, IFA, IFN-γ, IL-17, Lipid A, lipopolysaccharide, Lipovant, MONTANIDE™, N-acetyl-muramyl-L-alanyl-D-isoglutamine, Pam3CSK4, quil A, trehalose dimycolate, or zymosan. In some embodiments, the additional adjuvant induces a mixed type 1 / type 17 immune response.

[0162] In some embodiments, the additional adjuvant is an immunomodulatory molecule that enhances the immune response. For example, the immunomodulatory molecule can be a cytokine, chemokine, or immune stimulant, a recombinant version of any of the foregoing, or a nucleic acid encoding any of the foregoing.

[0163] Examples of immunomodulatory cytokines include interferons (e.g., IFNα, IFNβ, and IFNγ), interleukins (e.g., IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-17, and IL-20), tumor necrosis factors (e.g., TNFα and TNFβ), erythropoietin (EPO), FLT-3 ligand, gIp10, TCA-3, MCP-1, MIF, MIP-1α, MIP-1β, RANTES, macrophage colony-stimulating factor (M-CSF), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage colony-stimulating factor (GM-CSF), as well as functional fragments of any of the foregoing.

[0164] In some embodiments, provided compositions include an immunomodulatory chemokine that binds to a chemokine receptor, e.g., a CXC, CC, C, or CX3C chemokine receptor. Exemplary chemokines include Mip1α, Mip-1β, Mip-3α (Larc), Mip-3β, Rantes, Hcc-1, Mpif-1, Mpif-2, Mcp-1, Mcp-2, Mcp-3, Mcp-4, Mcp-5, Eotaxin, Tarc, Elc, I309, IL-8, Gcp-2 Gro-α, Gro-β, Gro-γ, Nap-2, Ena-78, Gcp-2, Ip-10, Mig, I-Tac, Sdf-1, and Bca-1 (Blc), and functional fragments of any of the foregoing.

[0165] G. Additional Medications In certain embodiments, the compositions provided herein also comprise one or more additional agents, such as, but not limited to, an anti-cancer agent (e.g., a chemotherapeutic agent), an immunotherapeutic agent, an immunomodulatory agent, and / or an anti-angiogenic agent.

[0166] In some embodiments, the composition further comprises an additional anti-cancer agent, hi some embodiments, the additional anti-cancer agent is selected from the group consisting of bevacizumab, bleomycin, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, etoposide, gemcitabine, letrozole, olaparib, tamoxifen, topotecan, trabectin, CTLA4 antibody, PD-1 antibody, PD-L1 antibody, and TGFβ antibody.

[0167] In some embodiments, the additional agent is a natural or synthetic anti-cancer agent, e.g., an anti-cancer agent described in "Cancer Chemotherapeutic Agents," American Chemical Society, 1995, WOFoye Ed.

[0168] In some embodiments, the anti-cancer agent comprises a small molecule.

[0169] In some embodiments, the anti-cancer agent is a receptor antagonist or blocker. In some embodiments, the chemotherapeutic agent is a VEGF receptor antagonist (e.g., vatalanib (PTK-787 / ZK222584), SU-5416, SU-6668, SU-11248, SU-14813, AZD-6474, AZD-2171, CP-547632, CEP-7055, AG-013736, IM-842, or GW-786034), VEGFtrap, EGFR and / or selected from the group consisting of HER2 antagonists (e.g., gefitinib, erlotinib, CI-1033, GW-2016, Herceptin, Iressa (ZD-1839), Tarceva (OSI-774), PKI-166, EKB-569, or HKI-272), integrin receptor antagonists, and protein kinase receptor antagonists (e.g., atrasentan). In some embodiments, the chemotherapeutic agent inhibits expression of HER2.

[0170] In some embodiments, the anti-cancer agent comprises a protein kinase antagonist, for example, an antagonist of mitogen-activated protein kinase (e.g., BAY-43-9006 or BAY-57-9006) or imatinib.

[0171] In some embodiments, the anti-cancer agent comprises a tubulin binding agent.

[0172] In some embodiments, the anti-cancer agent comprises an antibody. For example, chemotherapeutic antibodies include, but are not limited to, antibodies against cytokines (e.g., TGFβ), antibodies targeting surface molecules of cancer cells, and antibodies targeting growth factors or their receptors. Non-limiting examples of antibody chemotherapeutic agents include alemtuzumab, apolizumab, bevacizumab, daclizumab, cetuximab, ibritumomab, mitumomab, matuzumab, oregovomab, rituximab, vitaxin (vitronectin-like receptor antibody), DC101 (VEGFR2 antibody), ID09C3 (MHC class II monoclonal antibody), and IMC-1C11 (kinase insert domain receptor antibody).

[0173] In some embodiments, the anti-cancer agent comprises a cell cycle inhibitor.

[0174] In some embodiments, the anti-cancer drug comprises a cytokine inhibitor.

[0175] In some embodiments, the anti-cancer agent comprises a hypoxia-selective cytotoxin.

[0176] In some embodiments, the anti-cancer agent comprises a TNFα inhibitor, for example, etanercept.

[0177] In some embodiments, the anti-cancer agent comprises an interferon, for example, interferon beta.

[0178] In some embodiments, the anti-cancer agent comprises an interleukin, such as IL-10 or IL-12.

[0179] In some embodiments, the anti-cancer agent comprises an immunomodulatory agent, such as lenalidomide or thalidomide.

[0180] In some embodiments, the anti-cancer agent comprises an immune checkpoint inhibitor, hi some embodiments, the immune checkpoint inhibitor is an inhibitor of CTLA4, such as a CTLA4 antibody (e.g., ipilimumab (BMS), tremelimumab (AstraZeneca), and / or KAHR-102 (Kahr Medical)). In some embodiments, the immune checkpoint inhibitor is an inhibitor of PD-1, e.g., a PD-1 antibody (e.g., nivolumab (BMS), pembrolizumab / lambrolizumab (Merck), pidilizumab (Curetech), AMP-224 (GSK), AMP-514 (AstraZeneca), STI-A1110 (Sorrento), and / or TSR-042 (Tesaro). In some embodiments, the immune checkpoint inhibitor is an inhibitor of PD-L1 and / or PD-L2, e.g., a PD-L1 and / or PD-L2 antibody (e.g., RG-7446 (Roche), BMS-936559 (BMS), MEDI-4736 (AstraZeneca), MSB-0020718C (Merck), AUR-012 (Pierre Fabre Med), STI-A1010 (Sorrento). In some embodiments, the anticancer agent comprises a leukotriene antagonist.

[0181] In some embodiments, the anticancer agent comprises a DNA alkylating agent, such as a nitrogen mustard or a derivative thereof (e.g., bendamustine, chlorambucil, chlormethine (mechlorethamine), oxazaphosphorines (e.g., cyclophosphamide, ifosfamide, and trofosfamide)), melphalan, nitromine, uramustine), a nitrosourea (e.g., carmustine, lomustine, or streptozocin), an alkylsulfonate (e.g., busulfan), an ethylenimine (aziridine) (e.g., thiotepa or hexamethylmelamine), a metal salt (e.g., carboplatin, cisplatin, or oxaliplatin), or a hydrazine (e.g., altretamine, procarbazine, dacarbazine, or temozolomide).

[0182] In some embodiments, the anticancer drug comprises a platinum compound, such as, for example, cisplatin, oxaliplatin, carboplatin, satraplatin, tetraplatin, or iproplatin.

[0183] In some embodiments, the anticancer drug comprises a DNA intercalator, for example, an anthracycline such as daunorubicin, doxorubicin (adriamycin), liposomal doxorubicin (doxil), epirubicin, or idarubicin.

[0184] In some embodiments, the anti-cancer agent comprises a DNA minor groove binding compound.

[0185] In some embodiments, the anti-cancer agent comprises a DNA crosslinking agent.

[0186] In some embodiments, the anticancer agent comprises an antimetabolite, such as, for example, a pyrimidine or purine analog or antagonist, or a nucleoside diphosphate reductase inhibitor. Non-limiting examples of antimetabolites include cytarabine, 5-fluorouracil (5-FU), pemetrexed, tegafur / uracil, uracil mustard, floxuridine, fludarabine, gemcitabine, capecitabine, mercaptopurine, cladribine, thioguanine, methotrexate, pentostatin, or hydroxyurea.

[0187] In some embodiments, the anticancer drug comprises an inhibitor of DNA transcription, RNA translation, or protein expression. Non-limiting examples of DNA transcription inhibitors include topoisomerase I or II inhibitors (e.g., camptothecin, irinotecan, topotecan, epipodophyllotoxin, etoposide, teniposide, or tricyclic carboximides) and inhibitors of transcription factor complexes (e.g., inhibitors of ESX / DRIP130 / Sur-2 complex, etc.).

[0188] In some embodiments, the anti-cancer agent comprises a proteasome inhibitor, such as, for example, bortezomib.

[0189] In some embodiments, the anticancer agent comprises an enzyme, for example, asparaginase or pegylated asparaginase (pegaspargase).

[0190] In some embodiments, the anti-cancer agent comprises an oligonucleotide or polynucleotide.

[0191] In some embodiments, the anti-cancer agent comprises a histone deacetylase inhibitor, such as, for example, SAHA, MD-275, trichostatin A, CBHA, LAQ824, or valproic acid.

[0192] In some embodiments, the chemotherapeutic agent comprises a chemo-radiosensitizing or protecting agent.

[0193] In some embodiments, the anti-cancer agent comprises an inhibitor of an oncogene, for example, a P53 or Rb inhibitor.

[0194] In some embodiments, the anticancer agent comprises a plant-derived agent such as a taxane (e.g., paclitaxel or docetaxel), a vinca alkaloid (e.g., navelbine, vinblastine, vincristine, vindesine or vinorelbine), or a tropical alkaloid (e.g., colchicine or a derivative thereof).

[0195] In some embodiments, the anticancer agent comprises a quinazoline or a derivative thereof, such as afatanib, erlotinib, gefitinib, or lapatinib.

[0196] In some embodiments, the anti-cancer agent comprises an antimitotic agent, for example, an antimitotic peptide (e.g., phomopsin and dolastatin), an antimitotic carbamate derivative (e.g., combretastatin (A4) or amfetinil).

[0197] In some embodiments, the anticancer drug comprises steganacin.

[0198] In some embodiments, the anti-cancer agent includes hormone blockers, such as antiandrogens, antiestrogens, gonadotropin releasing hormone (GNrH) antagonists (e.g., abarelix), GNrH analogs, and aromatase inhibitors. Non-limiting examples of such antiandrogens include anandrolone, bicalutamide, casodex, cyproterone acetate, flutamide, mitotane, and nilutamide. Non-limiting examples of antiestrogens include droloxifene, raloxifene, tamoxifen, trioxyphene, and zindoxifene. Non-limiting examples of GNrH analogs include leuprorelin (leuprolide), buserelin, goserelin, and triptorelin. Non-limiting examples of aromatase inhibitors include aminoglutethimide, anastrozole, fadrozole, formestane or letrozole, and testalactone. Additional examples of hormone blockers include finasteride.

[0199] In some embodiments, the anti-cancer agent comprises a hormone or a derivative thereof, such as an estrogen (e.g., estramustine (T-66), 17-β-estradiol (including derivatives ICI 164,384 or ICI 182,780), a gestagen, or a progestin (e.g., megestrol).

[0200] In some embodiments, the anticancer drug comprises a piperazine derivative, for example, piprobroman.

[0201] In some embodiments, the anti-cancer agent comprises a glutathione analog, for example, TLK-286.

[0202] In some embodiments, the anti-cancer agent comprises a biological response modifier, for example, aldesleukin or denileukin diftitox.

[0203] In some embodiments, the anti-cancer agent comprises a matrix metalloprotease inhibitor, such as marimastat, TIMP-1, or TIMP-2.

[0204] In some embodiments, the anticancer agent comprises a complex of a rare earth element, for example a lanthanide complex.

[0205] In some embodiments, the anti-cancer drug comprises a metal, such as zinc, that has anti-cancer effects.

[0206] In some embodiments, the anticancer drug comprises a photochemically activated drug, such as a porfimer, photofrin, a benzoporphyrin derivative, a pheophorbide derivative, merocyanine 540 (MC-540), or tin etioporphyrin.

[0207] In some embodiments, the anti-cancer drug comprises an agent used in photochemotherapy treatment, for example, a psoralen used in conjunction with ultraviolet light therapy.

[0208] In some embodiments, the anti-cancer agent comprises an aromatic nitro compound, such as RSU-1069, RB-6145, or CB-1954. In some embodiments, the chemotherapeutic agent comprises a nitroxyl or N-oxide, such as SR-4233.

[0209] In some embodiments, the anti-cancer agent comprises an antisense RNA or DNA, for example, oblimersen.

[0210] In some embodiments, the anticancer agent comprises a halogenated pyrimidine analog, for example, bromodeoxyuridine or iododeoxyuridine.

[0211] In some embodiments, the additional agent comprises an angiogenesis inhibitor, such as DC-101, neovastat, tetrathiomolybdate, a thymidine phosphorylase inhibitor, or TNP-470.

[0212] In some embodiments, the additional agents include antibiotics (including macrolides), antifungals, or antiparasitics, which may or may not have anti-cancer effects. Non-limiting examples of antibiotics that may be used as additional agents include acridine, actinomycin, amsacrine, ansamitocin, anthramycin, bleomycin, chloromycin, dactinomycin, distamycin, duocarmycin, geldanamycin, ketoconazole, ribromycin, maytansine, mithramycin, mitomycin, mitoxantrone, netropsin, nitroimidazoles (e.g., benznidazole, metronidazole, misonidazole, nimorazole, NLA-1, NLP-1), nitroacridine, nitroquinoline, nitropyrazoloacridine, olivomycin, phleomycin, phthalanilides (e.g., propamidine or stilbamidine), pipendimol, pirikamycin, rifamycin, rhizoxin, squalamine, tanespimycin (17-allylaminogeldanamycin), or a derivative or salt of any of the foregoing.

[0213] In some embodiments, the additional agent comprises an aziridoquinone (e.g., mitomycin C, BMY-42355, AZQ, or EO-9).

[0214] In some embodiments, the additional agent comprises misonidazole, NLP-1 or NLA-1, a 2-nitroimidazole such as a nitroacridine, a nitroquinoline, or a nitropyrazoloacridine.

[0215] In some embodiments, the additional agent comprises an anti-inflammatory agent, such as, for example, a steroid or a non-steroidal anti-inflammatory drug. Non-limiting examples of steroids include prednisone, prednisolone, methylprednisolone, dexamethasone, budenoside, fluocortolone, or triamcinolone. Non-limiting examples of additional anti-inflammatory agents include acetylsalicylic acid, mesalazine, ibuprofen, naproxen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miloprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen, indomethacin, sulindac, tolmetin, zomepirac. , nabumetone, diclofenac, fenclofenac, alclofenac, bromfenac, ibufenac, aceclofenac, acemetacin, fentiazac, clidanac, etodolac, oxypinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflunisal, flufenisal, piroxicam, tenoxicam, romoxicam, nimesulide, meloxicam, celecoxib, and rofecoxib.

[0216] In some embodiments, the additional agent comprises a bisphosphonate or a derivative thereof, such as minodronic acid or a derivative thereof (YM-529, Ono-5920, YH-529), zoledronic acid monohydrate, ibandronate sodium hydrate, or clodronate disodium.

[0217] In some embodiments, the additional agent is in the form of a pharma- ceutically acceptable salt, hydrate and / or solvate. In some embodiments, the chemotherapeutic agent is in the form of an individual optical isomer, a mixture of individual enantiomers, or a racemate thereof. E. Nucleic acids In some embodiments, the composition comprises a nucleic acid (e.g., a DNA or RNA molecule) encoding a polypeptide antigen, such as an alpha-lactalbumin polypeptide, as described herein. In such embodiments, the composition may comprise a nucleic acid instead of or in addition to an antigen. In some embodiments, the composition comprises an expression vector comprising an open reading frame encoding a polypeptide, such as an alpha-lactalbumin polypeptide.

[0218] Upon uptake into a cell (e.g., muscle cells, antigen presenting cells (APCs), e.g., dendritic cells, macrophages, etc.), the DNA molecule may be present within the cell as an extrachromosomal molecule and / or may be integrated into the chromosome. DNA may be introduced into the cell in the form of a plasmid, which may remain as separate genetic material. Alternatively, linear DNA may be introduced into the cell, which may be integrated into the chromosome. Optionally, when introducing DNA into a cell, a reagent may be added that promotes integration of the DNA into the chromosome.

[0219] II. Treatment method In one aspect, a method is provided that includes administering to a subject a therapeutically effective amount of a composition disclosed herein.

[0220] In some embodiments, provided herein are methods for treating or preventing cancer and / or inducing an immune response against cancer, e.g., breast cancer.

[0221] subject The methods described herein can be used to treat any subject in need thereof.

[0222] Generally, the subject to which the composition or formulation of the present disclosure is administered has an adaptive immune system. In some embodiments, the subject is a mammal. Examples of subjects include, but are not limited to, humans, livestock, dogs, cats, mice, rats, and transgenic species thereof. In some embodiments, the subject is a human.

[0223] In some embodiments, the subject has cancer or is at risk of developing cancer. For example, the subject may have been diagnosed with cancer. The cancer may be primary cancer or metastatic cancer. The subject may have cancer at any stage, for example, stage I, stage II, stage III, or stage IV, with or without lymph node involvement, and with or without metastasis. The provided compositions may prevent or reduce further growth of the cancer and / or otherwise ameliorate the cancer (e.g., prevent or reduce metastasis).

[0224] In some embodiments, the subject does not have cancer but has been determined to be at risk for developing cancer due to the presence of one or more risk factors, such as, for example, environmental exposure, the presence of one or more genetic mutations or variants, family history, etc.

[0225] In some embodiments, the subject is not diagnosed with cancer.For example, the provided compositions and formulations can be used as a preventive vaccine, for example, in individuals identified as at risk in one or more subpopulations for which prevention can be particularly effective.For example, for a vaccine against breast cancer, the subject can be, for example, a non-lactating woman.

[0226] In some embodiments, the cancer is breast cancer (e.g., primary breast cancer, metastatic breast cancer). In some embodiments, the breast cancer is triple negative breast cancer (negative for estrogen receptor (ER), progesterone receptor (PR), and HER2) or comprises cells that are triple negative. In some embodiments, the breast cancer is positive or comprises cells that are positive for at least one of ER, PR, and HER2.

[0227] In some embodiments, the subject has undergone surgery to remove at least a portion of breast tumor.In some embodiments, the subject has a genetic predisposition to develop breast cancer, for example, a mutation in BRCA1 or BRCA2 gene that is associated with such risk.In some embodiments, the subject has a family history of breast cancer.

[0228] In some embodiments, the cancer expresses or overexpresses a polypeptide, or a polypeptide whose fragment(s) and / or variant(s) are used as an antigen in the provided compositions or formulations. For example, in some embodiments, the cancer (e.g., breast cancer) expresses or overexpresses alpha-lactalbumin.

[0229] In some embodiments, the subject has been, will be, or is concurrently administered an additional therapeutic agent. The additional therapy may include, for example, surgical resection, radiation therapy, chemotherapy, and / or other modes of immunotherapy. In some embodiments, the additional therapy includes an additional agent described herein.

[0230] For example, in some embodiments, the subject is receiving, will be receiving, or is concurrently receiving an anti-cancer therapy that includes an anti-cancer agent as described herein.

[0231] In some embodiments, administration is timed relative to the additional therapy in a manner that avoids interfering with the immunogenicity of the compositions as described herein.

[0232] In some embodiments, the subject is receiving an additional therapy, and as a result of the additional therapy, the subject does not exhibit clinical symptoms of the disease of the subject to be treated, e.g., clinically measurable tumor. However, in some embodiments, the subject is determined to be at risk of disease recurrence or progression. For example, if the disease is cancer, the subject may be determined to be at risk of cancer recurrence or progression, in some embodiments, e.g., proximal to the original tumor site and / or metastatic site. Such subjects can be further classified into high-risk and low-risk subjects. Classification can be performed, for example, based on characteristics observed before and / or after treatment with the additional therapy. These characteristics are known in the clinical field and can be defined for each type of cancer. Typical characteristics of high-risk subgroups include invasion into adjacent tissues and / or lymph node metastasis. Thus, for example, the pharmaceutical compositions described herein can be administered to a subject to induce an anti-cancer response and prevent cancer recurrence or progression.

[0233] Route of Administration The compositions (including pharmaceutical compositions) disclosed herein may be administered by any suitable route of administration, including oral, parenteral, and other routes of administration described in the "Formulations and Pharmaceutical Compositions" subsection of the "Compositions" section. In some embodiments, a therapeutically effective amount of the composition is administered by a systemic route of administration (e.g., via oral or parenteral administration). In some embodiments, a therapeutically effective amount of the composition is administered topically. In some embodiments, a therapeutically effective amount of the composition is administered by subcutaneous, intradermal, subdermal, or intramuscular injection.

[0234] dose In certain embodiments, the therapeutically effective amount comprises more than one dose, for example, at least two doses or at least three doses.In some embodiments, the therapeutically effective amount comprises three or less doses, for example, exactly three doses.In some embodiments, each dose is administered at intervals of one week or more, for example, at least two weeks or more, at least three weeks or more, or at least four weeks.In some embodiments, each dose is administered at intervals of about four weeks.

[0235] In some embodiments, each dose contains about the same amount of antigen, hi some embodiments, each dose contains about the same amount of antigen and the same amount of carbohydrate.

[0236] In some embodiments, an initial dose is administered and the subject is monitored for immunological and / or clinical response. Suitable means of immunological monitoring include using the patient's peripheral blood mononuclear cells (PBMCs) as responders and tumor cells or antigens as stimulants to determine memory or recall responses. Immunological response can also be determined by the presence of delayed inflammatory responses at the administration site. One or more doses following the initial dose can be suitably given, for example, on a monthly, semi-monthly, or weekly basis, until the desired effect is achieved. Additional booster or maintenance doses can then be given as needed, especially if immunological or clinical benefits appear to have subsided.

[0237] An appropriate dose may be determined, for example, by reference to the plasma concentration obtained in a subject to which the dose is administered. For example, the maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve from time 0 to infinity (AUC(0-4)) may be used. Doses include those that produce particular desired values ​​of Cmax and AUC(0-4).

[0238] The dosage may depend on a variety of factors, such as the activity of the particular antigen or composition; the route of administration; the time of administration; the rate of excretion or metabolism of components in the particular composition used; the duration of treatment; other drugs, compounds and / or substances used in combination with the particular antigen composition; the age, sex, weight, medical condition, general health, and previous medical history of the subject; and similar factors well known in the medical arts.

[0239] Generally, the "therapeutically effective amount" of the composition described herein is the minimum amount effective to produce the desired immunological, preventive or therapeutic effect.For example, in some embodiments, the therapeutically effective amount is the amount that can induce an effective humoral or cellular T cell response, or in some embodiments, an effective systemic immune response in the subject to be treated.Such an effective amount generally depends on certain factors such as those described above.

[0240] In some embodiments, each dose contains about 1 μg to about 20 mg, e.g., about 1 μg to about 5 mg, about 50 μg to about 2 mg, or about 100 μg to about 1 mg of antigen. For example, in some embodiments, each dose contains about 1 μg, about 2 μg, about 3 μg, about 4 μg, about 5 μg, about 10 μg, about 15 μg, about 20 μg, about 30 μg, about 40 μg, about 50 μg, about 60 μg, about 70 μg, about 80 μg, about 90 μg, about 100 μg, about 150 μg, about 200 μg, about 250 μg, about 300 μg, about 350 μg, about 400 μg, about 450 μg, about 500 μg, about 550 μg, about 600 μg, about 650 μg. g, about 700 μg, about 750 μg, about 800 μg, about 850 μg, about 900 μg, about 950 μg, about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, about 10 mg, about 15 mg, about 20 mg, or any value therebetween of antigen.

[0241] In some embodiments, each dose contains about 1 μg to about 20 mg of carbohydrate, e.g., about 10 μg to about 10 mg, about 50 μg to about 5 mg, about 100 μg to about 2 mg, or about 100 μg to about 1 mg. For example, in some embodiments, each dose contains about 1 μg, about 2 μg, about 3 μg, about 4 μg, about 5 μg, about 10 μg, about 15 μg, about 20 μg, about 30 μg, about 40 μg, about 50 μg, about 60 μg, about 70 μg, about 80 μg, about 90 μg, about 100 μg, about 150 μg, about 200 μg, about 250 μg, about 300 μg, about 350 μg, about 400 μg, about 450 μg, about 500 μg, about 550 μg, about 600 μg, about 650 μg, About 700 μg, about 750 μg, about 800 μg, about 850 μg, about 900 μg, about 950 μg, about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, about 10 mg, about 15 mg or about 20 mg of carbohydrate or any value therebetween.

[0242] response In some embodiments, administration of the composition induces an immune response.

[0243] Generally, the immune response can include a humoral immune response, a cellular immune response, or both.

[0244] The humoral response can be measured, for example, by standard immunoassays for antibody levels in serum samples from subjects who have been administered the pharmaceutical composition.

[0245] Cellular immune responses are responses that typically involve T cells and can be measured in vitro or in vivo. For example, general cellular immune responses can be measured as T cell proliferation activity in cells (e.g., peripheral blood leukocytes (PBLs)) sampled from a subject at an appropriate time after administration of a pharma- ceutically acceptable composition. For example, PBMCs can be incubated with a stimulator for an appropriate period of time and then [3H] thymidine incorporation can be measured. The percentage of proliferating T cells can be determined using flow cytometry. Another method of measuring cellular immunity includes measuring the frequency of circulating T cells secreting inflammatory type 1 and / or type 17 cytokines in response to an antigen.

[0246] In some embodiments, the immune response comprises an antigen-specific T cell immune response, which may comprise, for example, CD4+ T cells, CD8+ T cells, or both. In some embodiments, the T cell immune response comprises a type 1 or type 17 proinflammatory T cell response. In some embodiments, the T cell immune response comprises both a type 1 and type 17 proinflammatory T cell response.

[0247] If the antigen is expressed on a cell, administration of the composition may elicit an immune response against that cell, for example, if the antigen is a tumor-associated antigen, administration of the composition may elicit an immune response against tumor cells expressing the antigen.

[0248] In some embodiments, the administration causes a reduction in granuloma formation in the subject compared to a reference level. For example, the reference level can be the level of granuloma formation observed in a subject administered a composition comprising complete Freund's adjuvant. In some embodiments, the reference level is the level of granuloma formation observed in a subject administered a composition comprising incomplete Freund's adjuvant. A "reduction in granuloma formation" can be characterized, for example, by one or more of a reduction in granuloma formation, granulomas that are less severe, granulomas that are less severe more rapidly, and granulomas that resolve (partially or completely) more rapidly.

[0249] cell therapy In some embodiments, methods are provided that include administering to subject cells (e.g., antigen-presenting cells or progenitor cells thereof) that have been contacted in vitro with a composition disclosed herein, or cells generated from such cells, e.g., antigen-primed antigen-presenting cells or antigen-specific lymphocytes.

[0250] IV. Preparation method In one aspect, a method for making the compositions or formulations disclosed herein is provided. In general, such a method comprises mixing an aqueous solution containing an antigen with an emulsion containing a carbohydrate and a metabolizable oil. Suitable antigens, carbohydrates, and metabolizable oils, as well as suitable ratios between two or more components, include those described herein, for example, in the "Compositions" section.

[0251] For example, in some embodiments, the ratio of aqueous solution to emulsion is about 1:2 to about 2:1 (v / v). In some embodiments, the ratio of aqueous solution to emulsion is about 1:1 (v / v).

[0252] V.Applications In one aspect, there is provided a method of using a composition or formulation disclosed herein for the manufacture of a medicament for preventing, treating, or ameliorating a disease or condition, e.g., cancer.

[0253] The present invention is further illustrated by the following examples, which should not be construed as limiting. All references, patents and published patent applications cited throughout this application, as well as the figures, are hereby incorporated by reference.

[0254] [Example] Example 1: A single vaccination with α-lactalbumin in complete Freund's adjuvant (CFA) induced both type 1 and type 17 inflammatory T cell immune responses Previously published studies have shown that vaccination of mice with recombinant murine α-lactalbumin inhibits the growth of both spontaneous and transplantable breast tumors when used in either prophylactic or therapeutic protocols. In the experiments in which tumor growth inhibition was observed, CFA was used as an adjuvant.

[0255] In this example, the type of immune response induced by α-lactalbumin in CFA was characterized by examining the splenocyte frequencies of type 1 (IFNγ-producing) and type 17 (IL-17-producing) T cells in mice administered the α-lactalbumin / CFA composition.

[0256] Mice were administered a single subcutaneous injection of 100 μg of recombinant mouse α-lactalbumin (containing 200 μg of H37Ra Mycobacterium tuberculosis) in CFA. As shown in Figure 1, the mean splenocyte frequencies of α-lactalbumin-specific T cells producing IFNγ (type 1) and IL-17 (type 17) inflammatory T cells reached levels of 1 / 6,700 and 1 / 12,700, respectively (Figure 1).

[0257] Thus, a single injection of the α-lactalbumin / CFA composition was sufficient to induce an inflammatory immune response involving both type 1 and type 17 T cells.

[0258] Example 2: Development of alternative adjuvants that induce both type 1 and type 17 T cell responses As Example 1 shows, the antigen / CFA composition induces both type 1 and type 17 T cell responses, suggesting that CFA is an effective immunostimulatory adjuvant.

[0259] Unfortunately, CFA cannot be used as an adjuvant for human vaccination due to its toxic effects, primarily related to the induction of unresolved granulomas and abscesses at the vaccination site.To develop alternative, non-toxic adjuvants that mimic CFA by inducing similar high frequencies of α-lactalbumin-specific type 1 and type 17 T cells, we tested a series of adjuvants with the aim of "reverse engineering" the optimized type 1 / type 17 adaptive immune response elicited by CFA. Adjuvants tested included: 1) CFA at 200 μg / vaccination, 2) triterpene glycoside GPI-0100 used at 200 μg / vaccination, 3) Sigma lipid A (Ribi adjuvant) used at 50 μg / vaccination, 4) ASO2B lipid A at 50 μg / vaccination, 5) unmethylated CpG DNA used at 100 μg / vaccination, 6) α-galactosylceramide (α-Gal-Cer) at 10 μg / vaccination, 7) β-glucan peptide at 200 μg / vaccination in IFA, and 8) zymosan at 200 μg / vaccination in IFA. Each vaccine dose contained 100 μg of recombinant mouse α-lactalbumin protein in 100 μL of aqueous solution emulsified with 100 μL of adjuvant prepared according to manufacturer's recommendations when available. In the absence of such recommendations, adjuvants were prepared according to instructions provided in references showing the induction of substantial immune responses. Of the adjuvants tested with recombinant mouse α-lactalbumin, β-glucan peptide / IFA and zymosan / IFA were the only adjuvants that were associated with tumor immunity and induced type 1 and type 17 T cells at frequencies similar to those observed when CFA was used as an adjuvant (Figure 2).

[0260] In subsequent preclinical studies of in vivo breast tumor growth inhibition, the only immunogen / adjuvant combination that provided significant inhibition of 4T1 mouse breast tumor growth comparable to that observed using α-lactalbumin / CFA (Figure 3A; P<0.02) was α-lactalbumin with zymosan in IFA as the adjuvant (Figure 3H; P<0.02). All other adjuvants tested did not provide any significant inhibition of breast tumor growth in vivo. failed to provide any inhibition in vivo (Figures 3B-G).

[0261] These results suggest that zymosan in combination with IFA is an effective adjuvant in vaccine compositions. Furthermore, an anti-cancer vaccine containing zymosan, IFA, and an antigen expressed on cancer cells successfully inhibited tumor growth in vivo.

[0262] Example 3: Development of a non-toxic adjuvant that induces both type 1 and type 17 responses A significant portion of the toxic effects induced by CFA is very likely due to the IFA used to suspend killed Mycobacteria tuberculosis bacteria. IFA is often used as a stand-alone adjuvant to induce type 2 regulatory T cells to produce antibodies. IFA is prepared from non-metabolizable oils, including paraffin oil. These non-metabolizable oils remain for long periods of time and promote antigen presentation. However, this long-term persistence may contribute substantially to the unresolved granulomas and abscesses at the vaccination site observed with CFA. Therefore, we explored alternatives to IFA to develop a non-toxic alternative adjuvant acceptable for use in human vaccination that would induce high frequencies of antigen-specific type 1 and type 17 inflammatory T cells along with the antigen. This alternative could then be used together with zymosan as a vaccine adjuvant.

[0263] MONTANIDE™ ISA51VG (Seppic, Paris, France) was tested as a potential replacement for IFA. MONTANIDE™ ISA51VG is a GMP-grade mixture of highly refined mineral oil (DRAKEOL™ 6VR) and a surfactant (mannide monooleate). When mixed with an aqueous phase immunogen in a 50 / 50 ratio, it results in a water-in-oil emulsion. Similar to IFA, this water-in-oil emulsion acts as a stand-alone vaccine to enhance the immune response. MONTANIDE™ ISA51VG serves as a replacement for MONTANIDE™ ISA51. The difference between both grades is the origin of the oleic acid (mannide monooleate) used to manufacture the surfactant. The oleic acid used to manufacture MONTANIDE™ ISA51 is of animal origin. Due to concerns about Bovine Spongiform Encephalopathy (BSE) and other transmissible spongiform encephalopathies, the oleic acid used in MONTANIDE® ISA51VG is of vegetable origin. Since 2006, MONTANIDE® ISA51VG (hereafter referred to simply as "MONTANIDE®" in this example) has been used in over 150 human clinical trials worldwide involving over 10,000 patients. Detailed composition, manufacturing process, analytical controls, and stability data are available in Drug Master Files (DMF) or Common Technical Documents (CTD) registered in various countries (DMF Type IV in the United States). In the United States, BBMF Nos. 9756 and 10870; and in the United States, BBMF Nos. 12130 and 14167).

[0264] To test the suitability of Montanide™ as an adjuvant component, 6-8 week old female BALB / cJ mice were administered a single dose of an emulsion containing 100 µg recombinant mouse α-lactalbumin and 200 µg zymosan in either 100 µL IFA or 100 µL MONTANIDE™. Four weeks after vaccination, splenocyte frequencies of inflammatory type 1 (IFNγ) and type 17 (IL-17) T cells were measured by ELISPOT analysis. Data in Figure 4 show the mean spot forming units (SFU) of recall responses to 50 µg / mL recombinant mouse α-lactalbumin minus the mean background response of cultures without recall antigen (mean background < 5 SPU per assay).

[0265] As shown in Figure 4, when zymosan and MONTANIDE™ were used as adjuvants, production of both type 1 and type 17 inflammatory T cells was induced. However, the level of induction was much lower than that achieved using zymosan in IFA as an adjuvant. Thus, multiple administrations of a vaccine with zymosan / MONTANIDE™ as an adjuvant may be required to achieve the high T cell frequencies associated with inhibition of tumor growth.

[0266] These results indicate that an adjuvant containing zymosan in a metabolizable oil can support antigens in eliciting both type 1 and type 17 immune responses.

[0267] Example 4: Alpha-lactalbumin / Zymosan / MONTANIDE™ Vaccine To determine the effective dose required to provide high frequencies of α-lactalbumin-specific type 1 / type 17 T cells using the zymosan / MONTANIDE™ adjuvant combination, female BALB / c mice were administered one or more doses of 200 μL of an emulsion containing equal amounts (by weight) of α-lactalbumin and zymosan. Each dose contained 100 to 1000 μg each of α-lactalbumin and zymosan.

[0268] Recombinant mouse α-lactalbumin (FLAG-N-mαlac-C-HIS) was dissolved in sterile USP grade water and zymosan was suspended in MONTANIDE™ ISA51VG. Four weeks after the final vaccination, splenocytes were subjected to ELISPOT analysis using capture / antibody pairs specific for mouse IFNγ, IL-5, and IL-17 to assess splenocyte frequencies of generated type 1, type 2, and type 17 T cell lineages, respectively.

[0269] Groups of three mice were given one, two, or three doses, spaced 4 weeks apart. Four weeks after the final dose, splenocyte frequencies of type 1 inflammatory T cells, type 17 inflammatory T cells, and type 2 regulatory T cells were measured by ELISPOT analysis using capture / antibody pairs specific for mouse IFNγ, IL-17, and IL-5, respectively.

[0270] As shown in Figure 5, all doses tested (100 μg, 250 μg, 500 μg, and 1000 μg of α-lactalbumin and zymosan, respectively) induced both type 1 and type 17 responses after the third dose. A consistent production of high frequencies of type 1 / type 17 T cells occurred after three doses of an emulsion containing 1 mg α-lactalbumin / 1 mg zymosan (Figure 5).

[0271] Furthermore, no abscesses were observed at any dose, and all granulomas generated at the vaccination site were completely resolved within 1-2 weeks after vaccination. No long-term adverse effects were observed. α-lactalbumin / Zymosan / MONTANIDE™ is an effective immunogen / adjuvant combination to induce α-lactalbumin-specific type 1 and type 17 T cells at a frequency usually sufficient to inhibit breast tumor growth without inducing unresolved granulomas and abscesses at the vaccination site.

[0272] Taken together, the results described in Examples 2-3 show that α-lactalbumin / zymosan / IFA induces type 1 / 17 T cell immunity and inhibition of breast tumor growth similar to vaccination with α-lactalbumin / CFA. When zymosan is suspended in MONTANIDE™ instead of IFA, the resulting water-in-oil emulsion induces antigen-specific type 1 / 17 inflammatory T cells at a lower frequency than observed with IFA when used with the appropriate antigen. Furthermore, multiple high-dose vaccinations with α-lactalbumin / zymosan / MONTANIDE™ emulsion induce type 1 / 17 T cell frequencies associated with inhibition of breast tumor growth without inducing abscesses or unresolved granulomas. Thus, vaccination with α-lactalbumin / zymosan / MONTANIDE™ emulsion induces type 1 / 17 immunity associated with effective inhibition of breast tumor growth.

[0273] Example 5: Alpha-lactalbumin / Zymosan / MONTANIDE™ Vaccine To assess whether the zymosan adjuvant in MONTANIDE™ was responsible for the toxic effects, histopathology and biometry of mice vaccinated with recombinant α-lactalbumin / zymosan / MONTANIDE™ were examined.

[0274] Test Design Three groups of 25 mice each (groups A, B, and C) were administered one, two, or three doses, respectively. Each group was subdivided into five subgroups of five mice each, and each subgroup received: 1) a control vaccine; 2) a vaccine containing 100 μg of recombinant mouse α-lactalbumin (FLAG-N-mαlac-C-HIS variant); 3) a vaccine containing 1000 μg of recombinant mouse α-lactalbumin (FLAG-N-mαlac-C-HIS variant); 4) a vaccine containing 100 μg of recombinant human α-lactalbumin (HISTEV-N-hαlac-COOH variant); and 5) a vaccine containing 1000 μg of recombinant human α-lactalbumin (HISTEV-N-hαlac-COOH variant). All vaccines were water-in-oil emulsions containing equal amounts of aqueous phase recombinant alpha-lactalbumin as the target antigen and oil phase zymosan as the adjuvant in MONTANIDE™ ISA51VG.

[0275] As outlined in Table 2, group A mice received a single dose, group B mice received two doses at one-month intervals, and group C mice received three doses at one-month intervals.

[0276] [Table 2]

[0277] Materials and Methods Recombinant α-lactalbumin The open reading frame cDNA nucleotide sequences of mouse α-lactalbumin (NCBI Reference Sequence: NM_010679.1) and human α-lactalbumin (NCBI Reference Sequence: NM_002289.2) were modified to ensure optimized protein folding and production in prokaryotic expression systems by replacing mammalian codons with more efficient prokaryotic sequences encoding the same amino acids (Dapcel, Cleveland, OH). Optimized DNA sequences were synthesized de novo (GeneArt, Regensburg, Germany). Mouse α-lactalbumin DNA was inserted into the pET3a expression vector (GeneArt) to provide recombinant mouse α-lactalbumin containing an N-terminal FLAG tag and a C-terminal 6×His tag (FLAG-N-mαlac-C-HIS). Human α-lactalbumin DNA was also inserted into a pET3a expression vector (GeneArt) to provide recombinant human α-lactalbumin containing a 6×His tag linked to its N-terminus, along with the tobacco etch virus nuclear inclusion endopeptidase (TEV protease), which served as a cleavage site for removing the 6×His tag from the recombinant human α-lactalbumin protein (HISTEV-N-hαlac-COOH). Plasmids containing these inserts were transformed into E. coli strain BL21Star (Invitrogen, Carlsbad, CA). After induction with isopropyl β-D-1-thiogalactopyranoside (IPTG; Amresco, Solon, OH), high-level expressing colonies were selected and sequenced to confirm proper orientation and alignment. The 6×His-tagged protein was purified under denaturing and reducing conditions using nickel-nitrilotriacetic acid (Ni-NTA) affinity chromatography (Qiagen Sciences, Germantown, MD). Prior to in vitro use, the protein was purified by reverse-phase high performance liquid chromatography (HPLC) to obtain endotoxin-free protein.

[0278] water Sterile USP grade water was purchased (Corning) and used to solubilize the recombinant α-lactalbumin protein in the aqueous phase of the emulsion.

[0279] Zymosan Zymosan A was purchased (Sigma-Aldrich) and used as a vaccine adjuvant.

[0280] MONTANIDE® MONTANIDE® ISA51VG was purchased (Seppic) and used as a solvent to suspend the zymosan and to maintain and stabilize the emulsion phase.

[0281] Vaccine preparation A stock solution was made by adjusting the recombinant α-lactalbumin protein solution to a concentration of 10 mg / ml in sterile USP grade water. Zymosan was suspended in MONTANIDE™ ISA51VG at a concentration of 10 mg / ml to make a stock solution. To vaccinate with a high dose of 1000 μg recombinant α-lactalbumin + 1000 μg zymosan, one 3.0 ml syringe was loaded with the aqueous recombinant α-lactalbumin solution and locked into a double female Luer lock connector, and another syringe was loaded with an equal volume of the oil phase zymosan suspension and locked into the other end of the connector.

[0282] The emulsification included two stages: pre-emulsification at a very slow speed and final emulsification at a high speed. The syringe plunger containing the aqueous recombinant α-lactalbumin was fully depressed so that both phases were in one syringe. During the slow pre-emulsion stage, the entire formulation was slowly and repeatedly passed from one syringe to the other via the connector, taking 4 seconds for each plunge, for a total of 30 cycles (each cycle took 8 seconds to complete). At the end of this pre-emulsion stage, the speed was dramatically increased, thereby performing 80 additional complete cycles as quickly as possible. The entire emulsion was then placed in one syringe and connected to a sterile 26-gauge needle.

[0283] The creation of a stable emulsion was confirmed prior to vaccination by a drop test. An emulsion was considered stable if it maintained its structural integrity for at least 5 min when a droplet of the emulsion was placed in a beaker filled with water. 200 μl of emulsion was injected subcutaneously in the dorsal neck to provide high dose vaccine (1000 μg recombinant α-lactalbumin + 1000 μg zymosan). To create emulsions containing low dose vaccine (100 μg recombinant α-lactalbumin + 100 μg zymosan), stock reagents were diluted to 10% of the original concentration in an appropriate solvent prior to preparing the emulsion.

[0284] Mice and vaccination Six- to seven-week-old female BALB / cJ mice were purchased (Jackson Laboratory, Bar Harbor, ME) and vaccinated at 8 to 10 weeks of age.

[0285] Mice were injected subcutaneously in the dorsal neck with 200 μl of emulsion for each dose. All vaccinations were administered dorsally, starting proximal to the back of the scalp, approximately 1.5 cm from each previous vaccination, and continuing in a caudal direction.

[0286] To facilitate accurate injection, mice were immobilized under isoflurane anesthesia before each dose was administered. After each dose was administered, mice were housed and maintained in microisolator cages with free access to sterile food and water at all times. Mice were observed daily for behavioral changes, including changes in social activity, isolation, changes in appearance or grooming behavior, excessive attention to the injection site, excessive scratching, etc.

[0287] Biometrics Baseline body weights and temperatures were obtained immediately prior to each dosing and every 3 days thereafter. Changes in body weight and temperature during the experiment were plotted as percentage deviation from baseline, with body weight on day 0 set to 100%. Body temperature was obtained using an Optris LS IR thermometer (Micro-Epsilon, Raleigh, NC), with the temperature probe positioned the same distance from the xiphoid process for each measurement. Liver, spleen, and kidney weights were measured at necropsy and calculated as a percentage of total body weight for each mouse.

[0288] autopsy Mice from each group were housed in a single cage, and each mouse was individually differentiated with a distinct permanent ear punch and then a temporary tail marker. Mice were euthanized 14–16 days after the final vaccination.

[0289] On the day of necropsy, one cage at a time was placed under a chemical fume hood where the necropsy was performed. Mice were observed for grooming patterns and the condition of the injection site.

[0290] Body temperature and weight were recorded, and the mouse was placed in a chamber connected to an isoflurane vaporizer supplying 97.5% pure oxygen and 2.5% isoflurane. After deep anesthesia, the mouse was placed ventral side up, the chest was wiped with a 70% isopropyl alcohol prep pad, and the heart was punctured with a 1.0 ml syringe and a 22-gauge needle. After approximately 0.5–0.8 ml of whole blood was collected, the mouse was cervically dislocated and a midline abdominal incision was made in the abdominal wall with surgical scissors from the lower abdomen to the xiphoid process to expose the abdominal contents. The diaphragm was then incised and the rib cage was cut. The vena cava was cut to evacuate the perfusion, and a 26-gauge needle on a 30 ml syringe filled with sterile cold PBS was inserted into the left ventricle for perfusion. The mouse was slowly perfused with a total volume of 30 ml of cold PBS. The spleen, liver, and kidneys were removed and weighed, then placed in 10% phosphate-buffered formalin. The remaining tissue to be harvested was then carefully removed and placed in fixative. After 24 hours, the tissue was removed, washed in PBS, and placed in 70% ethanol until processed for histopathology. The brains of mice in group C were fixed for an extended period before being stored in 70% ethanol.

[0291] histopathology These tissues were collected for histopathology: kidney, brain, colon, liver, lung, ovary, spleen, heart, uterus, skin (injection site), stomach, bladder, breast, and small intestine. Starting with groups B and C, skin samples were collected from each injection site to allow for evaluation of the healing process of the injection sites over time. For group C, additional tissues were collected and analyzed, including thymus, mesenteric lymph nodes, and submandibular salivary glands. For group C, tissue processing was also modified to include 1) distension of the bladder and lungs with formalin as part of the recovery process; and 2) formalin fixation of the brain within the skull with the calvaria removed for a total of 5 days instead of a 24-hour fixation. All tissues were fixed overnight in 10% phosphate-buffered formalin, washed in PBS, and stored in 70% ethanol until processing. Tissues were embedded in paraffin, cut, mounted on slides, and stained with hematoxylin and eosin. Tissue sections were analyzed by a veterinary pathologist.

[0292] result Figures 6-8 show the changes in body weight during the observation period, Figures 9-11 show the changes in body temperature in each group and subgroup, and Figures 12-14 show the weights of the spleen, liver, and kidneys recorded at necropsy and expressed as a percentage of total body weight.

[0293] No issues of mortality or severe morbidity were noticeably evident throughout the study period. Morbidity appeared to be limited to the injection site, and hair growth did not fully heal or resume during the 14-15 days following the first dose, or the 45- or 75-day observation periods for mice that received two or three doses. Overall, mice exhibited normal behavior with regard to eating, drinking, and socializing. In general, mice gained weight over the course of the study, except for a slight, temporary weight loss immediately following each vaccination, from which the mice quickly recovered. (See Figures 6-8).

[0294] Mice receiving the highest doses of vaccine (M1000 and H1000) showed considerable interest at the injection site 6 days after injection. The injection site was typically hairless with a granulomatous appearance by day 9 and had begun to form a scab by day 12. By the time of euthanasia on days 14-15 (for group A), the scab had resolved and the injection site appeared almost completely healed but was still hairless. This pattern of irritation, hair loss, scab formation, and healing resolution was also observed with the second and third vaccinations in the M1000 and H1000 subgroups. For example, mice in group B showed substantial healing from the first vaccination by the time the second vaccination was administered. The initial injection sites of mice receiving multiple doses showed continued improvement throughout the course of the study but did not show complete healing or complete restoration of hair growth during the 45-day observation period for mice receiving two doses or the 75-day observation period for mice receiving three doses.

[0295] However, the degree of healing generally correlated with the age of the injection site, with the oldest injected sites appearing to be the healthiest. Conversely, the areas of hair loss around the injection sites were generally greater in the older injected sites. It is not clear why this occurred, but it may be that the mice found it easier to scratch the first injection site (closest to the head).

[0296] Mice that received three doses of low doses of human α-lactalbumin (H100) but not mouse α-lactalbumin (M100) showed the same pattern of irritation, hair loss, scabbing, and healing resolution as mice injected with the highest vaccine dose. This aggressive response was restricted to mice vaccinated with human α-lactalbumin protein and was only evident after the third vaccination. Without wishing to be limited to any particular theory, the aggressive response in these mice may be related to the enhanced immunogenicity of the heterologous antigen and the high level of immunity achieved in response to three doses of the heterologous antigen.

[0297] Figures 15 and 16 show the resolution of granulomas at the injection sites over time. Figure 15 shows photos of mice taken approximately 2 weeks after the second injection and approximately 6 weeks after the first injection. The blue arrow indicates the first injection site and the red arrow indicates the second injection site. As Figure 15 shows, the first injection site has an improved appearance compared to the second injection site, indicating resolution of the granulomas over time.

[0298] FIG. 16 shows the average grade of oil granulomas at injection sites using the following grading system: 0, normal; 1, minimal; 2, mild; 3, moderate; 4, severe. For each injection site, the average grade was calculated for all mice (n=25) in all treatment groups. Error bars represent ±SE. All injection sites initially showed moderate oil granulomas on average. However, over time, these granulomas substantially resolved, with significant improvement noted between the first and third immunizations (P<0.001) and between the second and third immunizations (P<0.05) at the experimental endpoint.

[0299] The results of histopathological analysis of the mice are shown in Tables 3A and 3B (group A; single dose), Tables 4A and 4B (group B; two doses), and Tables 5A-5C (group C; three doses). The following symbols are used in Tables 3A, 3B, 4A, 4B, 5A, 5B, and 5C:

[0300] n = normal (no lesions) BI = biliary inflammation FI = focal inflammation OG = oily granuloma (injection site) Ab = abscess At = atrophy GCH = germinal center hyperplasia LPH = lamina propria hyperplasia MH = myeloid hyperplasia em = epicardial calcification NP = nephropathy FC = steatosis FN = focal necrosis u = ulcer n / s = no intercept ns = not recognized np = not present grade: 1 = Minimum 2 = Mild 3 = moderate 4 = severe In group A (single dose) (Tables 3A and 3B), no adverse organ effects were observed in mice vaccinated with either human or mouse α-lactalbumin (M and H subgroups). Lesions were found at the injection site; these were oily granulomas containing the injected material, macrophages, and some neutrophils. In some mice, abscesses were found at the injection site. The abscesses suggest that bacterial contamination of the injected material occurred during the injection procedure. Most other lesions found were considered incidental, as they were minimal to mild and were also found in controls. Hepatic foci of inflammatory cells were observed in many mice and may be related to the injection site lesions.

[0301] [Table 3]

[0302] [Table 4]

[0303] In Group B (2 doses) (Tables 4A and 4B), liver foci of inflammatory cells were observed in many mice. The liver foci were random, biliary, and consisted mostly of lymphocytes, with occasional neutrophils and macrophages. Some liver foci were bone marrow foci (bone marrow hyperplasia in the liver). Liver lesions included mild bile duct inflammation and may not have adversely affected hepatocytes and liver function.

[0304] The bone marrow hyperplastic splenic lesions observed in some mice likely represented a reaction to the injection site lesion. The germinal center hyperplastic splenic lesions observed in some mice may have been a reaction to the injection site lesion and / or a response to antigen.

[0305] Mammary gland tissue was often present in the skin sections, but not in the breast sections which contained only muscle.

[0306] Abscesses were observed in some mice at the site of injection and consisted of neutrophils, which may represent sterile abscesses that did not contain or contained bacteria; bacteria were often absent from the lesions.

[0307] [Table 5]

[0308] [Table 6]

[0309] In Group C (three doses) (Tables 5A-5C), the histopathological results were similar to those of Groups A and B. The most severe skin lesions were present at the third (most recent) injection site. No organ-specific toxic lesions were observed. Most of the lesions observed, which were not dose-correlated, were incidental.

[0310] Liver lesions were also most severe in the high-dose mice. These lesions resembled lesions caused by Helicobacter hepaticus, which is commonly seen in immunocompromised mice. To evaluate the cause of these liver lesions, livers from three mice with many hepatic inflammatory foci (containing infiltrates mainly containing lymphocytes and some macrophages with occasional necrosis) were stained with Steiner stain. Positive control sections of human stomach in which bacteria were present were also included. None of the mouse livers with inflammatory loci had lesions that stained positive for bacteria. Thus, the liver lesions observed in these mice may not have been due to infection with Helicobacter hepaticus.

[0311] [Table 7]

[0312] [Table 8]

[0313] [Table 9]

[0314] FIG. 17 shows an overview of the severity of focal hepatic inflammation in all groups.

[0315] In summary, these results indicate that the liver lesions were random, focal, biliary, and predominantly mild and benign, with the most severe lesions occurring in the high-dose mice, and may not have adversely affected hepatocytes and liver function.

[0316] Example 6: Prophylactic inhibition of spontaneous breast cancer growth by immunization with α-lactalbumin / zymosan / MONTANIDE™ MMTV-neu mice can be used as a mouse model of spontaneous mammary cancer. MMTV-neu mice express the neu protooncogene under the control of the mouse mammary tumor virus (MMTV) long terminal repeat and develop spontaneous mammary cancer with a 50% incidence by 205 days of age. (See, e.g., Guy CT, et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA. 1992;89:10578-10582).

[0317] To test the ability of the α-lactalbumin / zymosan / MONTANIDE™ vaccine to inhibit breast cancer growth, MMTV-neu mice are administered three or more doses of α-lactalbumin in zymosan and Montanide, for example at doses of 1000 μg each of zymosan and Montanide. Additional groups of mice may be used as controls or for comparison, and may include mice administered 1) α-lactalbumin in CFA (positive control); 2) α-lactalbumin in zymosan and IFA; or 3) zymosan in MONTANIDE™ without antigen (negative control), respectively.

[0318] To evaluate the ability of the alpha-lactalbumin / zymosan / MONTANIDE™ vaccine to inhibit cancer growth before it appears, the first, second, and third doses may all be administered well before the mice are expected to develop tumors, e.g., 6-10 weeks, and tumor incidence and / or size are examined and compared between groups.

[0319] Example 7: Inhibition of the growth of established breast cancer by immunization with α-lactalbumin / zymosan / Montanide To test the ability of the alpha-lactalbumin / zymosan / MONTANIDE™ vaccine to inhibit the further growth of already established breast cancer, mice from one or more suitable cancer models are administered three or more doses of alpha-lactalbumin in zymosan and MONTANIDE™, for example at doses of 1000 μg each of zymosan and MONTANIDE™. The experiments and grouping of mice are similar to those described in Example 4, except that administration may be performed at different times depending on the cancer model. For example, at least one, two, or three doses are administered to mice of a certain age, where a significant proportion of mice in that cancer model have already established cancer, according to known characteristics of the mouse model. Alternatively, at least one, two, or three doses are administered after the mouse shows at least one sign of having developed at least one tumor, for example when the mouse has at least one palpable tumor.

[0320] Any of a variety of suitable cancer models can be used to test the effect on established breast tumors included. As a non-limiting example, MMTV-PyVT transgenic mice constitutively express an activated form of the neu oncogene in mammary tissue and develop aggressive palpable mammary tumors by 5 weeks of age. (See, for example, Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992; 12: 954-961). Thus, MMTV-PyVT mice can be used to evaluate the effect on spontaneous tumor growth.

[0321] Transplantable breast cancer models may also be suitable, for example, mice may be inoculated by injection with tumor cells of a breast cancer cell line such as 4T1.

[0322] Tumor size at one or more different time points (eg, time after immunization, time after tumor cell inoculation, etc.) is examined and compared between groups.

[0323] Example 8: Phase I clinical trial of an alpha-lactalbumin vaccine in patients with non-metastatic triple-negative breast cancer at high risk of recurrence Treatment of triple-negative breast cancer is inadequate and hindered by the lack of viable therapeutic targets. The results described in Examples 2-4 and other preclinical studies suggest that a vaccine containing α-lactalbumin (antigen) and zymosan (in MONTANIDE™ vehicle) can induce immune responses consistent with effective prevention and treatment of breast tumors. Moreover, this vaccine has great potential for treating triple-negative breast cancer in humans.

[0324] An open-label Phase I clinical trial is planned to determine the vaccine dose and schedule for use in future trials. The trial will include an initial dose escalation phase to determine the maximum tolerated dose (MTD) of the alpha-lactalbumin / zymosan / MONTANIDE™ vaccine in patients with non-metastatic triple-negative breast cancer (TNBC). Cohort expansion will then be used to explore the relationship between vaccine dose and immune response in order to select doses for Phase II trials.

[0325] FIG. 18 shows the study scheme illustrating the timeline of dose administration, toxicity assessment, and blood sampling for immunological monitoring.

[0326] Objectives and Endpoints Primary Objective: To determine the maximum tolerated dose (MTD) of α-lactalbumin / zymosan / MONTANIDE™ in patients with non-metastatic TNBC.

[0327] Secondary objective: Measure immune responses to the vaccine, focusing on its ability to induce inflammatory T cell responses consistent with tumor protection. This will be determined using an ELISPOT assay to measure peripheral blood frequencies of T cells producing interferon gamma (IFNγ; type 1) and IL-17 (type 17) in response to recombinant human alpha-lactalbumin. Based on these immunological assays, identify the lowest immunological dose (LID), the lowest dose that produces an immunological effect.

[0328] Immunological response is defined as the post-treatment occurrence of 1 / 30,000 IFNγ-secreting (type 1) and / or IL-17-secreting (type 17) T cells elicited from peripheral blood mononuclear cells in response to α-lactalbumin / zymosan / MONTANIDE™ vaccination. LID is defined as the lowest tolerated dose observed in patients with an immunological response >1 / 10.

[0329] Exploratory objective: To determine the optimal immunization dose (OID) of α-lactalbumin vaccine in a population of operable TNBC patients based on ELISPOT assays. The OID is defined as the dose at which most patients generated an immune response as defined above. If multiple dose levels have the same number of immune responders, the lowest of these dose levels is defined as the OID. The OID is: <MTDでなければならない。

[0330] Relative Objectives: Examine the cellular response to α-lactalbumin / zymosan / MONTANIDE™ vaccination in a population of operable TNBC patients using ELISPOT assays of IFNγ and IL-17 production in response to α-lactalbumin stimulation. · Examine the humoral response to α-lactalbumin / zymosan / MONTANIDE™ vaccination in an operable TNBC patient population using an ELISA assay.

[0331] Safety Objective: Determine the incidence of adverse events (drug-related and treatment emergencies).

[0332] subject Between 40 and 60 subjects who meet the following inclusion criteria but are not excluded by any of the following exclusion criteria are enrolled. These subjects represent a high-risk population with operable TNBC. Subjects are enrolled after completion of all standard treatments, which may include chemotherapy, surgery, or radiation therapy. Chemotherapy may be administered either pre- or post-operatively.

[0333] Inclusion Criteria: The study is open to both men and women and members of all racial and ethnic groups. Potential subjects must meet all of the following inclusion criteria to be eligible for enrollment: Histologically proven invasive breast cancer · Primary tumors are estrogen receptor (ER) negative (ER<1% of cells), progesterone receptor (PR) negative (PR<1% of cells), and HER2 negative (0-1+ IHC or FISH ratio <2.0, signals <6 / cell) ("triple-negative breast cancer"). High risk, defined as either o Pathological stage IIA, IIB, IIIA, IIIB, or IIIC according to AJCC6; or o Residual invasive carcinoma of the breast or regional lymph nodes after preoperative chemotherapy Within 6 months of last active treatment (chemotherapy, radiotherapy, or surgery) and <12 months since starting treatment for current cancer. Treatment prior to enrollment must be consistent with the most current NCCN guidelines available on the website at the address “www.nccn.org / ” immediately following “https: / / .” Age > 18 ECOG (Eastern Performance Oncology Group) performance status 0-1. (See e.g. Oken M,Creech R,Tormey D,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol. 1982;5:649-655; or the website at the address immediately following “https: / / ” “ecog-acrin.org / resources / ecog-performance-status”). Adequate major organ function defined as WBC>3,000 / mcl; hemoglobin>10.0 gm / dL, platelets>100,000 / mcL, total bilirubin within normal range, ALT / AST<2.5 times upper limit of normal (ULN), and serum creatinine<1.5 x ULN · Serum prolactin levels should be < upper limit of normal (ULN). Ability to understand and willingness to provide and sign a written informed consent document · Archival tissue is available for potential correlative studies (e.g., assays for α-lactalbumin expression or tumor-infiltrating lymphocytes), but tumors do not need to demonstrate α-lactalbumin overexpression for enrollment. · Subjects agree not to use alternative therapies from the time of informed consent until 30 days after the last vaccine injection.

[0334] Exclusion Criteria Any of the following characteristics would exclude a potential subject from this study: - Receiving cytotoxic chemotherapy within 4 weeks of starting the study Radiation therapy within 4 weeks of starting the study Failure to recover from toxicities of prior therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grades 0 to 1, excluding alopecia and grade 2 neuropathy. · The need for systemic corticosteroid use (except for physiological replacement defined as prednisone 10 mg / day or equivalent). The need for immunosuppression (e.g., due to a history of organ transplantation) Known HIV infection Active or planned breastfeeding or pregnancy Taking or planning to take oral contraceptives Refusal to use effective non-hormonal contraception. Acceptable methods of contraception include, but are not limited to, barrier contraception (diaphragms or condoms), non-hormonal intrauterine devices, and vasectomy for the male partner. Receipt of other investigational medicinal products within the past 4 weeks. Known recurrence or metastasis History of another active invasive malignancy within 5 years of starting the study History of allergic reactions to α-lactalbumin, human breast milk (except lactose intolerance), zymosan, or any other medications used in this study. Uncontrolled intercurrent illnesses, including but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina, cardiac arrhythmias, or psychiatric / social conditions that limit compliance with study requirements Known hyperprolactinemia Current treatment with drugs known to cause hyperprolactinemia Known allergy to penicillin Target Screening Subjects will be screened by review of medical records, medical history, and physical examination. Pathology materials will also be reviewed to determine study eligibility. Screening will be performed within 4 weeks prior to administration of the first vaccination.

[0335] Potentially eligible subjects who consent will undergo laboratory testing including a complete blood count (CBC) with differential, prolactin level, and comprehensive metabolic profile (total protein, albumin, calcium, total bilirubin, alkaline phosphatase, AST, glucose, BUN, creatinine, sodium, potassium, chloride, bicarbonate, and ALT), as well as a pregnancy test.

[0336] Subjects are not required to undergo scans to rule out metastatic disease, but will be managed according to American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) guidelines. Potential study subjects with signs or symptoms of metastatic disease or unexplained abnormal alkaline phosphatase or liver function test results will undergo standard of care imaging to rule out the presence of metastases.

[0337] Vaccine preparations cGMP grade Zymosan A (Sigma-Aldrich Fine Chemicals, Buchs, Switzerland) is suspended in GMP grade MONTANIDE™ ISA51VG (Seppic, Fairfield, NJ) to create the Zymosan / MONTANIDE™ suspension. MONTANIDE™ ISA51VG is a light oil / surfactant solvent that facilitates the creation of water-in-oil emulsions and is much more metabolizable than the incomplete Freund's adjuvant (IFA) oil used to formulate CFA. GMP grade recombinant human alpha-lactalbumin (rhαlac) (List Biologicals, Campbell, CA) in USP grade H2O is mixed with the Zymosan / MONTANIDE™ suspension to generate the water-in-oil emulsion. Each emulsion formulation is made by a clinical pharmacist on the day of its use and administered to each patient within 2 hours of shipping.

[0338] Medication and Administration Subjects will receive the alpha-lactalbumin / zymosan / MONTANIDE™ vaccine by subcutaneous administration at rotational sites (left thigh, right thigh, and abdomen). Subjects will receive three doses at 4-week intervals. In the initial dose escalation phase, patients will be sequentially enrolled into one of six different dose levels (shown in Table 6), each consisting of cohorts of 1-6 patients, until the MTD is identified. Dose level 1 is 1% of the dose routinely given to mice in previous preclinical studies. No intrapatient dose escalation will be allowed.

[0339] [Table 10]

[0340] mcg = micrograms MONTANIDE™ is used as the solvent at all dose levels.

[0341] Dose escalation will proceed within each cohort according to the accelerated titration dose escalation scheme summarized in Table 7. Dose limiting toxicities (DLTs) generally correspond to CTCAE version 5 grade 2 or higher toxicities. (CTCAE version 5 can be found on the website whose address is "ctep.cancer.gov / protocolDevelopment / electronic_applications / docs / CTCAE_v5_Quick_Reference_8.5x11.pdf" immediately followed by https: / / .) If grade 1 toxicity is observed, the dose escalation scheme shown in Table 8 will be used.

[0342] [Table 11]

[0343] [Table 12]

[0344] After identifying the MTD, the dose level expansion phase will be initiated. The MTD will be expanded to 10 subjects and immunological correlation studies will be performed in all 10 subjects. Table 9 outlines the scheme of the dose expansion phase.

[0345] [Table 13]

[0346] After expansion of the MTD, successively lower doses will be expanded to 10 patients until the lowest dose level associated with an immune response is expanded.

[0347] evaluation Subjects will be evaluated according to the study calendar shown in Table 10. Subjects will undergo a medical history and physical examination (including breast exam) at screening, Day 0, every 4 weeks, and at the Day 84 visit.

[0348] Subjects will be evaluated for toxicity 4 weeks after the last vaccination or until all toxicities have resolved to grade 0-1, whichever occurs later. All patients will be contacted or seen for long-term follow-up to allow for long-term monitoring of toxicity, recurrence, and survival.

[0349] As part of this study, subjects who have received at least one vaccination will be considered evaluable for toxicity. To allow for safe dose escalation, subjects who discontinue treatment before receiving three doses of the investigational vaccine in the absence of dose-limiting toxicity (DLT) will be replaced. Subjects who develop DLTs after any number of doses will be considered fully evaluable and will not be replaced, even if they have not undergone immunological correlation testing.

[0350] [Table 14]

[0351] 1 The screening visit will occur within 28 days of visit day 0. Scans are not required to rule out metastatic disease. 2 All visits ±3 business days. 3 CMP (global metabolic profile) includes total protein, albumin, calcium, total bilirubin, alkaline phosphatase, AST, glucose, BUN, creatinine, sodium, potassium, chloride, bicarbonate, anion gap, and ALT. 4 ELISPOT frequencies of α-lactalbumin and ovalbumin specific T cells; culture supernatant levels of IFNγ and IL-17 flow cytometric measurement of the percentage of central and effector memory T cells; and direct ELISA measurement of α-lactalbumin antibody titers. 5 Allow >2 hours for vaccine preparation 6 After administration of the vaccine, vital signs are obtained every 15 minutes for 60 minutes and again at 120 minutes. Patients are observed for 120 minutes.

[0352] Example 9: Vaccine formulation containing zymosan suspended in MONTANIDE™ Other vaccine formulations containing adjuvants as disclosed herein may be produced and tested according to the present invention. For example, any antigen of interest, e.g., a polypeptide antigen, may be mixed with zymosan suspended in MONTANIDE™. The antigen of interest may be expressed, for example, on tumor cells and / or pathogenic organisms against which the vaccine formulation is designed to act.

[0353] The vaccine formulation is then tested by any of a variety of methods, as disclosed in this disclosure or as described below.

[0354] Antigen-specific recall responses To assess antigen-specific recall responses, mice are administered one or more doses of the vaccine formulation. Ten days after the last dose, lymph node cells are harvested from the mice. The lymph node cells are incubated in the presence of serial dilutions of antigen (either the antigen used in the vaccine formulation or an irrelevant antigen as a negative control). The cells are subjected to a proliferation assay. For example, cell cultures can be pulsed with labeled thymidine and a "stimulation index" can be calculated by dividing the (labeled) counts from cultures containing the antigen used in the vaccine formulation by the counts from cultures containing the irrelevant antigen. Enhanced proliferation in cultures containing the antigen used in the vaccine indicates an antigen-specific recall response.

[0355] Response characteristics Lymph node cells from mice administered one or more doses of the vaccine formulation can be analyzed in terms of cell surface markers (e.g., CD4+ vs. CD8+) (e.g., by flow cytometry) and / or by cytokine release (e.g., by ELISA or ELISPOT assays). The cytokine release profile may be indicative of the type of immune response (e.g., type 1, type 2, or type 17). A cytokine release profile indicative of both type 1 and type 17 responses is indicative of a potentially effective vaccine formulation.

[0356] Tumor growth inhibition Antitumor vaccine formulations contain an antigen of interest expressed on tumor cells. These formulations can be tested for their ability to inhibit tumor growth in appropriate animal tumor models. Controls can include formulations with adjuvants (Zymosan and MONTANIDE™) only (as negative controls) or one of the formulations containing the antigen of interest and a different adjuvant commonly used.

[0357] Medication Test Dosage trials may be performed using a range of amounts in each dose (e.g., a range of amounts of antigen of interest and / or zymosan) and / or times of administration to determine the effective amount of the vaccine formulation. Output measurements may include one or more of antigen-specific recall responses, response characteristics, or tumor growth inhibition (in the case of anti-cancer vaccine formulations).

[0358] Example 10: Emulsification Protocol To obtain an emulsion containing an antigen (e.g., a polypeptide antigen) and MONTANIDE™ ISA51, two silicone-free syringes connected by a connector (I or T connector) can be used to create high shear conditions to trap the aqueous droplets in the surrounding oil phase. The antigen may be dissolved in an aqueous solution, e.g., water or saline (most often PBS or NaCl 0.9% saline buffer), and one volume of this aqueous antigen solution can be mixed with one volume of MONTANIDE™ ISA51. The mixture can then be loaded into a device that includes, for example, two silicone-free syringes connected by an I connector, which is used to perform a pre-emulsification step that includes multiple (e.g., about 20) slow cycles (e.g., cycles lasting approximately 4 seconds), followed by an emulsification step that includes multiple (e.g., about 40) fast cycles. A cycle is defined as the transfer of the entire solution (aqueous phase and adjuvant) from a first syringe to the other syringe, followed by the transfer of the entire solution back to the original syringe.

[0359] Incorporation by Reference All publications, patents, and patent applications mentioned herein are herein incorporated by reference in their entirety as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

[0360] Equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein which equivalents are intended to be encompassed by the following claims. [Brief description of the drawings]

[0361] [Figure 1] Induction of inflammatory T cell immunity by vaccination with α-lactalbumin / complete Freund's adjuvant (CFA) emulsion. The mean splenocyte frequency of IFNγ (type 1) and IL-17 (type 17) producing inflammatory T cells was measured 4 weeks after vaccination of 6-8 week old BALB / c female mice (n=3) with 200 μl of water-in-oil emulsion containing 100 μg recombinant mouse α-lactalbumin and 200 μg of Mycobacteria tuberculosis H37RA strain in complete Freund's adjuvant (CFA). Error bars indicate ±SD. [Diagram 2] Comparison of several adjuvants with CFA in the induction of type 1 / type 17 T cell immunity. Splenocyte frequencies of type 1 and type 17 inflammatory T cells were measured 4 weeks after immunization of 6-8 week-old BALB / cJ female mice with 200 μL of emulsion containing 100 μg of recombinant mouse α-lactalbumin and conventional doses of various adjuvants, including CFA. Data are expressed as the mean α-lactalbumin-specific type 1 and type 17 spot-forming units (SFU) obtained using each test adjuvant divided by the SFU obtained on the same day using CFA as the "gold standard" adjuvant. The horizontal black dotted line indicates the frequency equivalent to that obtained using CFA as adjuvant (SFU induced using CFA=1). Some immunizations were performed twice, 2 weeks apart, and are shown ×2. [Diagram 3]Growth of 4T1 mouse mammary tumors using different α-lactalbumin / adjuvant combinations. Figure 3A shows that female BALB / cJ mice were vaccinated subcutaneously at 6–8 weeks of age with 200 μL of an emulsion containing 100 μg of recombinant mouse α-lactalbumin and 200 μg of CFA. Control mice were vaccinated with 200 μg of CFA alone. Two weeks after vaccination, mice were inoculated subcutaneously with 2 × 104 4T1 mouse mammary tumor cells and tumor growth was measured every other day using calipers. This same protocol was then used to measure tumor growth for various other adjuvants shown in Figure 2, including (Figure 3B) GPI-0100 x2, (Figure 3C) Sigma lipid A, (Figure 3D) AS02B lipid A, (Figure 3E) CpG DNA x2, (Figure 3F) CpG DNA+α-Gal-Cer x2, (Figure 3G) β-glucan peptide in IFA, and (Figure 3H) zymosan in IFA, using the manufacturer's recommended doses. Some vaccinations were given twice, 2 weeks apart, and are shown as x2. Asterisks indicate significant differences between test and control vaccinated mice (P<0.05). [Figure 4] Figure 1 shows induction of type 1 / type 17 inflammatory T cells using Zymosan / IFA, Zymosan / MONTANIDE™. Female BALB / cJ mice, 6-8 weeks old, were vaccinated with an emulsion containing 100 μg of aqueous phase recombinant mouse α-lactalbumin emulsified with 200 μg of zymosan in either 100 μL IFA or 100 μL MONTANIDE™. Four weeks after vaccination, splenocyte frequencies of inflammatory type 1 (IFNγ) and type 17 (IL-17) T cells were measured by ELISPOT analysis. Data show the mean spot forming units (SFU) of recall responses to 50 μg / mL recombinant mouse α-lactalbumin minus the mean background response of cultures without recall antigen (mean background < 5 SPU per assay). Error bars indicate ± SE. [Diagram 5]Results of vaccine dose testing are shown. Eight-week-old female BALB / cJ mice were subcutaneously vaccinated in the flank with 200 μl of emulsion containing equal amounts of α-lactalbumin and zymosan ranging from 100 to 1000 μg each. Recombinant mouse α-lactalbumin (FLAG-N-mαlac-C-HIS) was dissolved in sterile USP grade water and zymosan was suspended in MONTANIDE™ ISA51VG. Groups of three mice were vaccinated once, twice, or three times, each with four-week intervals. Four weeks after the final vaccination, splenocytes were subjected to ELISPOT analysis using capture / antibody pairs specific for mouse IFNγ, IL-5, and IL-17 to assess splenocyte frequencies of generated type 1, type 2, and type 17 T cell lineages, respectively. [Figure 6] 1 shows the change in body weight from the time of the first vaccination of single-vaccinated Group A mice in the toxicology study described in Example 5. [Figure 7] 1 shows the change in body weight from the time of the first vaccination of dually vaccinated Group B mice in the toxicology study described in Example 5. [Figure 8] Figure 1 shows the change in body weight from the time of the first vaccination of triple-vaccinated Group C mice in the toxicology study described in Example 5. Body weight changes were normalized to the body weight obtained on day 0 (set at 100%) and plotted as a percentage increase or decrease relative to this initial starting point. Body weights were recorded for each mouse at the same time. Arrows indicate the day(s) of vaccination. Error bars indicate ±SE. [Figure 9] 1 shows the change in body temperature from the time of the first vaccination of single-vaccinated Group A mice in the toxicology study described in Example 5. [Figure 10] 1 shows the change in body temperature from the time of the first vaccination in dually vaccinated Group B mice in the toxicology study described in Example 5. [Figure 11]Figure 1 shows the change in body temperature from the time of first vaccination of triple-vaccinated Group C mice in the toxicology study described in Example 5. The change in body temperature was normalized to the temperature obtained on day 0 (set as 100%) and plotted as a percentage increase or decrease relative to this initial starting point. Temperatures were recorded at the same time for each mouse. Arrows indicate the day(s) of vaccination. Error bars indicate ±SE. [Figure 12] 1 shows spleen, liver, and kidney weights recorded at necropsy for single vaccinated Group A mice in the toxicology study described in Example 5. [Figure 13] 1 shows spleen, liver, and kidney weights recorded at necropsy for double vaccinated Group B mice in the toxicology study described in Example 5. [Figure 14] Figure 1 shows spleen, liver, and kidney weights recorded at necropsy for triple-vaccinated Group C mice in the toxicology study described in Example 5. Weights were expressed as a percentage of total body weight, and the average percentages were plotted for each subgroup of mice (as shown in Table 2 in Example 5). Error bars indicate ±SE. [Figure 15] Figure 15 shows a representative appearance of the immunization site in a mouse subcutaneously administered Zymosan / MONTANIDE™ / α-lactalbumin emulsion, as further described in Example 5. Figure 15 shows a photograph of the mouse taken approximately 2 weeks after the second injection and approximately 6 weeks after the first injection. The blue arrow indicates the first injection site, and the red arrow indicates the second injection site. As Figure 15 shows, the first injection site has an improved appearance compared to the second injection site, indicating resolution of the granuloma over time. [Figure 16]Figure 1 shows the mean clinical endpoint scores for granulomas at three consecutive injection sites in BALB / c mice subcutaneously injected with Zymosan / MONTANIDE™ / α-lactalbumin emulsion, as further described in Example 5. Oily granulomas at the injection sites were commonly observed and were graded according to the following criteria: 0, normal; 1, minimal; 2, mild; 3, moderate; 4, severe. For each injection site, the mean was calculated for all mice (n=25) in all treatment groups. Error bars represent ±SE. [Figure 17] 1 shows a summary of the severity of focal hepatitis in all groups in the toxicology study described in Example 5. [Figure 18] 1 shows a study scheme for the clinical trial described in Example 8. The scheme shows the timeline of dose administration, toxicity assessment, and blood sampling for immunological monitoring.

Claims

1. Carbohydrates, and 1. A composition comprising a metabolizable oil, (i) the composition further comprises an antigen; or (ii) the carbohydrate comprises a polysaccharide, and the composition comprises a mixture of at least two polysaccharides.

2. The composition of claim 1 , wherein the antigen is a tumor-associated antigen.

3. The composition of claim 1 , wherein the carbohydrate comprises a polysaccharide, the polysaccharide comprising a mixture of at least two polysaccharides.

4. The composition of claim 1 , wherein the composition comprises a tumor-associated antigen and the carbohydrate comprises a mixture of at least two polysaccharides.

5. The composition, (i) comprises a tumor-associated antigen, or 2. The composition of claim 1, comprising: a) a mixture of at least two polysaccharides and b) a carbohydrate having an antigen; and (iii) when the composition is administered to a subject, the composition is capable of inducing an antigen-specific T cell immune response, including both type 1 and type 17 proinflammatory T cell responses.

6. The composition of any one of claims 1 to 5, wherein the carbohydrate binds to a pattern recognition receptor.

7. The composition of claim 6, wherein the pattern recognition receptor is TLR2 or Dectin-1.

8. The composition according to any one of claims 1 to 7, wherein the mixture of polysaccharides comprises at least three polysaccharides.

9. 9. The composition of claim 1, wherein the polysaccharide, or each polysaccharide in the mixture of polysaccharides, is selected from the group consisting of chitin, dextran, glucan, lentanan, mannan, and combinations thereof.

10. The composition of any one of claims 1 to 9, wherein the polysaccharide or mixture of polysaccharides comprises a glucan.

11. The composition of claim 10, wherein the glucan is a β-glucan.

12. The composition of claim 11, wherein the β-glucan is a 1-3 β-glucan.

13. The composition of any one of claims 9 to 12, wherein the mixture of polysaccharides comprises a mixture of chitin, glucan, and mannan.

14. The composition of any one of claims 11 to 13, wherein at least 50% of the carbohydrate in the composition is β-glucan.

15. The composition of claim 13 , wherein the composition comprises zymosan.

16. The composition of any one of claims 1 to 15, wherein the metabolizable oil comprises a refined oil.

17. 17. The composition of claim 16, wherein the refined oil is a mineral oil.

18. 18. The composition of claim 17, wherein the refined mineral oil is DRAKEOL™ 6VR.

19. The composition of any one of claims 1 to 18, wherein the metabolizable oil comprises a biodegradable oil.

20. 20. The composition of claim 19, wherein the biodegradable oil is isopropyl myristate, squalene oil, squalane oil, vegetable oil, or a combination thereof.

21. 21. The composition of claim 20, wherein the biodegradable oil is a vegetable oil.

22. 22. The composition of claim 21, wherein the vegetable oil is selected from the group consisting of almond oil, castor oil, tallow oil, coconut oil, corn oil, cottonseed oil, olive oil, peanut oil, apricot kernel oil, safflower oil, and soybean oil.

23. The composition of any one of claims 1 to 22, wherein the metabolizable oil is a pharmaceutical grade oil.

24. The composition of any one of claims 1 to 23, further comprising a surfactant.

25. 25. The composition of claim 24, wherein the surfactant comprises mannide monooleate, isomannide monooleate, or a combination thereof.

26. 26. The composition of claim 25, wherein the surfactant comprises mannide monooleate.

27. 27. The composition of claim 26, wherein the composition comprises MONTANIDE™.

28. 28. The composition of claim 27, wherein the MONTANIDE(TM) is MONTANIDE(TM) ISA 51VG.

29. The composition of any one of claims 24 to 28, wherein the composition is a water and oil emulsion.

30. 30. The composition of claim 29, wherein the composition is a water-in-oil emulsion.

31. The composition of any one of claims 1 to 30, wherein the antigen comprises a polypeptide antigen.

32. The composition of claim 31 , wherein the polypeptide antigen is a retired autoantigen.

33. The composition of claim 32, wherein the polypeptide antigen comprises an alpha-lactalbumin polypeptide.

34. The composition of claim 33, wherein the alpha-lactalbumin polypeptide has an amino acid sequence comprising at least 8 consecutive amino acids of SEQ ID NO:

5.

35. 35. The composition of any one of claims 1 to 34, wherein the antigen and the carbohydrate are present in a ratio of about 10:1 to about 1:10 (w / w).

36. 36. The composition of claim 35, wherein the antigen and the carbohydrate are present in a ratio of about 1:1 (w / w).

37. The composition of any one of claims 1 to 36, further comprising a pharma- ceutically acceptable carrier.

38. The composition of any one of claims 1 to 37, further comprising an antibiotic.

39. A method comprising the step of administering to a subject a therapeutically effective amount of a composition according to any one of claims 1 to 38.

40. 40. The method of claim 39, wherein the subject is a mammal.

41. 41. The method of claim 40, wherein the subject is a human.

42. 42. The method of claim 40 or 41, wherein the subject is a non-lactating female subject.

43. The method of any one of claims 40 to 42, wherein the subject has cancer or is at risk of developing cancer.

44. The method of any one of claims 40 to 43, wherein the subject has not been diagnosed with cancer.

45. 45. The method of claim 43 or 44, wherein the cancer is breast cancer.

46. 45. The method of claim 43 or 44, wherein the breast cancer is metastatic breast cancer.

47. 45. The method of claim 43 or 44, wherein the breast cancer is a primary breast cancer.

48. 45. The method of claim 43 or 44, wherein the breast cancer is triple negative breast cancer.

49. The method of claim 43 or 44, wherein the cancer comprises cells that overexpress alpha-lactalbumin.

50. 50. The method of any one of claims 39-49, wherein the therapeutically effective amount comprises two or more doses.

51. 51. The method of claim 50, wherein the therapeutically effective amount comprises three or more doses.

52. 52. The method of claim 50 or 51, wherein the therapeutically effective amount comprises no more than three doses.

53. 53. The method of any one of claims 50 to 52, wherein each dose is administered at intervals of one week or more.

54. 54. The method of claim 53, wherein each dose is administered at least four weeks apart.

55. 55. The method of claim 54, wherein each dose is administered at intervals of about 4 weeks.

56. 56. The method of any one of claims 50 to 55, wherein each dose comprises approximately the same amount of antigen.

57. 57. The method of claim 56, wherein each dose comprises approximately the same amount of antigen and the same amount of carbohydrate.

58. 58. The method of any one of claims 39 to 57, wherein each dose comprises from about 1 μg to about 5 mg of antigen.

59. 60. The method of claim 58, wherein each dose comprises from about 50 μg to about 2 mg of antigen.

60. 60. The method of claim 59, wherein each dose comprises from about 100 μg to about 1 mg of antigen.

61. 61. The method of any one of claims 39 to 60, wherein the composition is administered by subcutaneous, intradermal, subdermal, or intramuscular injection.

62. The method of any one of claims 39 to 61, wherein administration of the composition induces an antigen-specific T cell immune response.

63. 63. The method of claim 62, wherein the T cell immune response comprises CD4+ T cells.

64. 64. The method of claim 62 or 63, wherein the T cell immune response comprises CD8+ T cells.

65. 65. The method of any one of claims 62 to 64, wherein the T cell immune response comprises a type 1 or type 17 proinflammatory T cell response.

66. 66. The method of claim 65, wherein the T cell immune response comprises both type 1 and type 17 proinflammatory T cell responses.

67. 67. The method of any one of claims 39 to 66, wherein administration causes a decrease in granuloma formation compared to a reference level.

68. 68. The method of claim 67, wherein the reference level is the level of granuloma formation observed in a subject administered a composition comprising complete Freund's adjuvant.

69. 69. The method of any one of claims 39-68, wherein the subject is receiving, will be receiving, or is simultaneously receiving an additional anti-cancer therapeutic agent.

70. 70. The method of claim 69, wherein the anti-cancer therapeutic comprises an anti-cancer drug.

71. 71. The method of claim 70, wherein the additional anti-cancer agent is selected from the group consisting of bevacizumab, bleomycin, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, etoposide, gemcitabine, letrozole, olaparib, tamoxifen, topotecan, trabectin, CTLA4 antibody, PD-1 antibody, PD-L1 antibody, and TGFβ antibody.

72. A composition comprising an alpha-lactalbumin polypeptide, zymosan, and MONTANIDE™, wherein the alpha-lactalbumin polypeptide comprises an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to the amino acid sequence of SEQ ID NO:

5.

73. The composition of claim 72, wherein the alpha-lactalbumin polypeptide comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

5.

74. A formulation comprising an alpha-lactalbumin polypeptide, zymosan, and a water-in-oil emulsion of MONTANIDE™, wherein the alpha-lactalbumin polypeptide and the zymosan are present in the formulation in a ratio of about 1:5 (w / w) to 5:1 (w / w), and the alpha-lactalbumin polypeptide comprises an amino acid sequence that is at least 80%, 85%, 90%, or 95% identical to the amino acid sequence of SEQ ID NO:

5.

75. 75. The formulation of claim 74, wherein the alpha-lactalbumin polypeptide comprises an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO:

5.

76. 76. A method of making a composition according to any one of claims 1 to 38, 72 or 73 or a formulation according to claim 74 or 75, comprising the step of mixing an aqueous solution comprising the antigen with an emulsion comprising the carbohydrate and the metabolisable oil.

77. 77. The method of claim 76, wherein the ratio of the aqueous solution to the emulsion is from about 1:2 to about 2:1 (v / v).

78. 78. The method of claim 77, wherein the ratio of the aqueous solution to the emulsion is about 1:1 (v / v).

79. Use of a composition according to any one of claims 1 to 38, 72 or 73, or a formulation according to claim 74 or 75, for the manufacture of a medicament for preventing, treating or ameliorating cancer.

Citation Information

Patent Citations

  • Multivalent breast cancer vaccine

    JP2015520129A

  • Methods for improving the efficacy of survivin vaccines in the treatment of cancer

    JP2016516083A

  • ovarian cancer vaccine

    JP2018526390A

  • Breast Cancer Vaccine

    US20120003254A1

  • Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer

    WO2017079303A1